WEBVTT

00:00:00.000 --> 00:00:02.779 So the abstracts that are selected were

00:00:02.779 --> 00:00:05.941 chosen by the speakers because they are

00:00:05.941 --> 00:00:09.269 the most clinically relevant and they are

00:00:09.269 --> 00:00:12.153 grouped in areas of clinical unmet need.

00:00:12.160 --> 00:00:15.303 Of course that doesn't mean that other

00:00:15.303 --> 00:00:17.826 abstracts that have been presented in

00:00:17.826 --> 00:00:21.230 the meeting or are as good or important,

00:00:21.230 --> 00:00:24.158 but you have to choose basically for this

00:00:24.158 --> 00:00:27.277 type of sessions important to remember.

00:00:27.280 --> 00:00:30.736 Again, many of the ash presentations.

00:00:30.740 --> 00:00:33.050 Basically are focused on preliminary

00:00:33.050 --> 00:00:35.813 data and subsequently some of those

00:00:35.813 --> 00:00:37.703 results might be modified and

00:00:37.703 --> 00:00:40.269 they are still not peer reviewed,

NOTE Confidence: 0.84681994

00:00:40.270 --> 00:00:45.466 so this is important to keep up in mind as we

NOTE Confidence: 0.84681994

00:00:45.466 --> 00:00:49.962 think about the data that will be presented.

NOTE Confidence: 0.84681994

00:00:49.970 --> 00:00:52.147 That there will be a recording of

NOTE Confidence: 0.84681994

00:00:52.147 --> 00:00:54.209 this session and all the sessions.

NOTE Confidence: 0.84681994

00:00:54.210 --> 00:00:56.744 This will be available and accessible as

NOTE Confidence: 0.84681994

00:00:56.744 --> 00:00:58.955 in during material in addition to the

NOTE Confidence: 0.84681994

00:00:58.955 --> 00:01:01.710 slides and at the end of the entire series,

NOTE Confidence: 0.84681994

00:01:01.710 --> 00:01:03.552 the six sessions you'll be able

NOTE Confidence: 0.84681994

00:01:03.552 --> 00:01:05.290 to claim your CME credit.

NOTE Confidence: 0.84681994

00:01:05.290 --> 00:01:08.224 For those of you who wants to claim it.

NOTE Confidence: 0.84681994

00:01:08.230 --> 00:01:10.384 After you answer a brief evaluation

NOTE Confidence: 0.84681994

00:01:10.384 --> 00:01:12.744 and some feedback about how we can

NOTE Confidence: 0.84681994

00:01:12.744 --> 00:01:14.746 improve the format of of the series.

NOTE Confidence: 0.8310966

00:01:17.160 --> 00:01:19.115 So today it's a pleasure

NOTE Confidence: 0.8310966

00:01:19.115 --> 00:01:20.679 to introduce the speakers.

NOTE Confidence: 0.8310966

2

00:01:20.680 --> 00:01:23.396 Sorry, there's a typo here is clearly

NOTE Confidence: 0.8310966

00:01:23.396 --> 00:01:26.148 this is not on my Lloyd update.

NOTE Confidence: 0.8310966

00:01:26.150 --> 00:01:28.110 It's the pediatric leukemia updates.

NOTE Confidence: 0.8310966

00:01:28.110 --> 00:01:31.568 So Doctor but also full start by.

NOTE Confidence: 0.8310966

00:01:31.570 --> 00:01:33.495 Talking to us about major

NOTE Confidence: 0.8310966

00:01:33.495 --> 00:01:35.420 updates from the meeting about

NOTE Confidence: 0.8310966

00:01:35.494 --> 00:01:37.558 Accutane for blastic leukemia.

NOTE Confidence: 0.8310966

00:01:37.560 --> 00:01:39.792 Then Doctor Nina Kadan Lotic will

NOTE Confidence: 0.8310966

00:01:39.792 --> 00:01:42.976 update us and I think some of the

NOTE Confidence: 0.8310966

00:01:42.976 --> 00:01:44.991 most important updates from the

NOTE Confidence: 0.8310966

00:01:44.991 --> 00:01:47.828 ASH meeting on pediatric leukemias,

NOTE Confidence: 0.8310966

00:01:47.830 --> 00:01:49.542 including LL, of course,

NOTE Confidence: 0.8310966

00:01:49.542 --> 00:01:52.110 and then at the end, Dr.

NOTE Confidence: 0.8310966

00:01:52.110 --> 00:01:55.050 Nikita Shah will present to us or

NOTE Confidence: 0.8310966

00:01:55.050 --> 00:01:58.244 will moderate the Q&A session for any

NOTE Confidence: 0.8310966

00:01:58.244 --> 00:02:01.020 questions that will arise about the

NOTE Confidence: 0.8310966

00:02:01.020 --> 00:02:03.974 talks that will be presented our the.

NOTE Confidence: 0.8310966

00:02:03.980 --> 00:02:04.824 Abstractly presented,

NOTE Confidence: 0.8310966

00:02:04.824 --> 00:02:07.356 but also about any other additional

NOTE Confidence: 0.8310966

00:02:07.356 --> 00:02:09.480 questions about pediatric hematology,

NOTE Confidence: 0.8310966

00:02:09.480 --> 00:02:12.056 and in general so we look forward

NOTE Confidence: 0.8310966

00:02:12.056 --> 00:02:14.970 to a very exciting discussion,

NOTE Confidence: 0.8310966

00:02:14.970 --> 00:02:18.099 and I would like to start by

NOTE Confidence: 0.8310966

00:02:18.099 --> 00:02:20.010 introducing Doctor Nikolai Bodos.

NOTE Confidence: 0.8310966

00:02:20.010 --> 00:02:22.758 If our associate professor of medicine,

NOTE Confidence: 0.8310966

00:02:22.760 --> 00:02:25.050 here in the hematologist auction,

NOTE Confidence: 0.8310966

00:02:25.050 --> 00:02:28.249 who focuses on Accutane for blastic leukemia.

NOTE Confidence: 0.6509804

00:02:36.010 --> 00:02:37.229 Nicola, you're on mute.

NOTE Confidence: 0.77839005

00:02:43.690 --> 00:02:47.670 He would go so almost there next.

NOTE Confidence: 0.8890739

00:02:47.670 --> 00:02:51.132 Let me see. Looking for

NOTE Confidence: 0.8890739

00:02:51.132 --> 00:02:52.556 my PowerPoint here ago.

NOTE Confidence: 0.84235924

00:02:55.790 --> 00:03:01.486 Right, and do you see a single screen?

NOTE Confidence: 0.84235924

00:03:01.490 --> 00:03:05.432 Yep OK alright. So hold on one second let

NOTE Confidence: 0.84235924

00:03:05.432 --> 00:03:09.763 me just get to the beginning of all this.

NOTE Confidence: 0.84235924

00:03:09.770 --> 00:03:11.730 Not sure why this happened this way.

NOTE Confidence: 0.88896275

00:03:14.660 --> 00:03:16.540 So I would like to start

NOTE Confidence: 0.88896275

00:03:16.540 --> 00:03:17.796 from a brief introduction,

NOTE Confidence: 0.88896275

00:03:17.800 --> 00:03:20.080 so this are my disclosures.

NOTE Confidence: 0.88896275

00:03:20.080 --> 00:03:22.666 And we will be talking about

NOTE Confidence: 0.88896275

00:03:22.666 --> 00:03:23.959 acute lymphoblastic leukemia,

NOTE Confidence: 0.88896275

00:03:23.960 --> 00:03:27.600 which is further abbreviated as a LL.

NOTE Confidence: 0.88896275

00:03:27.600 --> 00:03:29.768 This is still the disease of the young

NOTE Confidence: 0.88896275

00:03:29.768 --> 00:03:32.348 and I represent adult hematology here,

NOTE Confidence: 0.88896275

00:03:32.350 --> 00:03:34.702 so Nina will be talking to what's happening

NOTE Confidence: 0.88896275

00:03:34.702 --> 00:03:37.088 in this field in pediatric hematology.

NOTE Confidence: 0.88896275

00:03:37.090 --> 00:03:39.434 And we certainly learned a lot over the

NOTE Confidence: 0.88896275

00:03:39.434 --> 00:03:41.837 last years from our pediatric colleagues,

NOTE Confidence: 0.88896275

00:03:41.840 --> 00:03:44.344 so this shows you that about 6000 patients

NOTE Confidence: 0.88896275

00:03:44.344 --> 00:03:46.108 are diagnosed with acute lymphoblastic

NOTE Confidence: 0.88896275

00:03:46.108 --> 00:03:48.614 leukemia per year in the United States,

NOTE Confidence: 0.88896275

00:03:48.620 --> 00:03:50.310 and only about 2000 of

NOTE Confidence: 0.88896275

00:03:50.310 --> 00:03:51.662 them are actually adults.

NOTE Confidence: 0.88896275

00:03:51.670 --> 00:03:54.374 Median age of diagnosis, as you can see,

NOTE Confidence: 0.88896275

00:03:54.380 --> 00:03:56.690 is around 9 years old and about

NOTE Confidence: 0.88896275

00:03:56.690 --> 00:04:00.198 1500 deaths per year, most of them.

NOTE Confidence: 0.88896275

00:04:00.198 --> 00:04:01.590 Are adults.

NOTE Confidence: 0.88896275

00:04:01.590 --> 00:04:03.365 So these survival remains very

NOTE Confidence: 0.88896275

00:04:03.365 --> 00:04:04.785 different between pediatric LL

NOTE Confidence: 0.88896275

00:04:04.785 --> 00:04:06.408 patients and adult male patients,

NOTE Confidence: 0.88896275

00:04:06.410 --> 00:04:09.178 and you can see 5 year old survival

NOTE Confidence: 0.88896275

00:04:09.178 --> 00:04:11.612 is about 90% and children and

NOTE Confidence: 0.88896275

00:04:11.612 --> 00:04:14.456 still half of that in adults.

NOTE Confidence: 0.88896275

00:04:14.460 --> 00:04:17.280 So we're excited to have approvals

NOTE Confidence: 0.88896275

00:04:17.280 --> 00:04:19.160 for newbs CLL therapies.

NOTE Confidence: 0.88896275

00:04:19.160 --> 00:04:21.980 You can call them immuno therapies.

NOTE Confidence: 0.88896275

00:04:21.980 --> 00:04:23.860 This includes approval of

NOTE Confidence: 0.88896275

00:04:23.860 --> 00:04:26.210 Blinatumomab in 2017 by FDA.

NOTE Confidence: 0.88896275

00:04:26.210 --> 00:04:28.802 It's a bispecific T cell engager

NOTE Confidence: 0.88896275

00:04:28.802 --> 00:04:31.667 attacking CD 19 positive B cells

NOTE Confidence: 0.88896275

00:04:31.667 --> 00:04:33.257 including the lymphoblasts.

NOTE Confidence: 0.88896275

00:04:33.260 --> 00:04:37.020 Also in 2017 there was an approval notice

NOTE Confidence: 0.88896275

00:04:37.020 --> 00:04:39.838 amalgamation which is antibody drag Queen.

NOTE Confidence: 0.88896275

00:04:39.840 --> 00:04:42.990 You get attacking CD 22 on again

NOTE Confidence: 0.88896275

00:04:42.990 --> 00:04:46.490 B cells and finally approval of.

NOTE Confidence: 0.88896275

00:04:46.490 --> 00:04:48.630 It is a jungle occlusal.

NOTE Confidence: 0.88896275

00:04:48.630 --> 00:04:51.283 The car T cell therapy for younger

NOTE Confidence: 0.88896275

00:04:51.283 --> 00:04:53.749 patients with relapsed refractory disease.

NOTE Confidence: 0.88896275

00:04:53.750 --> 00:04:54.177 Again,

NOTE Confidence: 0.88896275

00:04:54.177 --> 00:04:57.166 attacking CD 19 cells on view lymphoblasts.

NOTE Confidence: 0.88896275

00:04:57.170 --> 00:04:59.528 This is for patients who are

NOTE Confidence: 0.88896275

00:04:59.528 --> 00:05:01.860 younger than 26 or younger,

NOTE Confidence: 0.88896275

00:05:01.860 --> 00:05:04.849 so the mechanism of action is bluna.

NOTE Confidence: 0.88896275

00:05:04.850 --> 00:05:07.839 Tumors represent on this slide is bite.

NOTE Confidence: 0.88896275

00:05:07.840 --> 00:05:09.532 Bispecific T cell engager,

NOTE Confidence: 0.88896275

00:05:09.532 --> 00:05:11.224 which attaches cytotoxic T

NOTE Confidence: 0.88896275

00:05:11.224 --> 00:05:12.959 cells to tumor cells.

NOTE Confidence: 0.88896275

00:05:12.960 --> 00:05:16.464 Through a CD 19 and by means of

NOTE Confidence: 0.88896275

00:05:16.464 --> 00:05:18.739 this attachment increases the.

NOTE Confidence: 0.88896275

00:05:18.740 --> 00:05:21.218 A pop ptosis of this tumor cells?

NOTE Confidence: 0.88896275

00:05:21.220 --> 00:05:23.831 So the studies which put this on

NOTE Confidence: 0.88896275

00:05:23.831 --> 00:05:26.807 the map and make it available to

NOTE Confidence: 0.88896275

00:05:26.807 --> 00:05:29.453 us are tower phase three study,

NOTE Confidence: 0.88896275

00:05:29.460 --> 00:05:31.488 which looked at Glenna to mob

NOTE Confidence: 0.88896275

8

00:05:31.488 --> 00:05:32.840 in relapsed refractory disease

NOTE Confidence: 0.88896275

00:05:32.902 --> 00:05:34.819 against conventional chemotherapy.

NOTE Confidence: 0.88896275

00:05:34.820 --> 00:05:36.880 And as you can see,

NOTE Confidence: 0.88896275

00:05:36.880 --> 00:05:38.940 there was a survival difference

NOTE Confidence: 0.88896275

00:05:38.940 --> 00:05:41.000 of 7.7 versus four months,

NOTE Confidence: 0.88896275

00:05:41.000 --> 00:05:42.644 which was statistically significant.

NOTE Confidence: 0.88896275

00:05:42.644 --> 00:05:44.288 Response rate was 44%,

NOTE Confidence: 0.88896275

00:05:44.290 --> 00:05:46.350 with 76% achieving mean negative,

NOTE Confidence: 0.88896275

00:05:46.350 --> 00:05:47.562 minimal residual disease.

NOTE Confidence: 0.88896275

00:05:47.562 --> 00:05:49.986 So this is all control study

NOTE Confidence: 0.88896275

00:05:49.986 --> 00:05:51.898 also blinatumomab it's an.

NOTE Confidence: 0.88896275

00:05:51.900 --> 00:05:54.210 It's a phase two study single arm

NOTE Confidence: 0.88896275

00:05:54.210 --> 00:05:56.928 looking at BLT amount for Peach paused,

NOTE Confidence: 0.88896275

00:05:56.930 --> 00:05:58.970 available patients and again you can

NOTE Confidence: 0.88896275

00:05:58.970 --> 00:06:01.517 see that the survival here for this

NOTE Confidence: 0.88896275

00:06:01.517 --> 00:06:03.387 patients with relapsed refractory pH.

NOTE Confidence: 0.88896275

00:06:03.390 --> 00:06:05.959 Posted bail is about 7.1 months with

NOTE Confidence: 0.88896275

00:06:05.959 --> 00:06:08.357 response rate of 36% among those patients.

NOTE Confidence: 0.88896275

00:06:08.357 --> 00:06:10.730 So the drug is approved for both

NOTE Confidence: 0.88896275

00:06:10.796 --> 00:06:12.176 relapse refractory pH positive

NOTE Confidence: 0.88896275

00:06:12.176 --> 00:06:14.880 and pH negative B cell L patients.

NOTE Confidence: 0.88896275

00:06:14.880 --> 00:06:17.600 The next drug is in its mother's advice

NOTE Confidence: 0.88896275

00:06:17.600 --> 00:06:20.379 and its antibody drag Queen you get.

NOTE Confidence: 0.88896275

00:06:20.380 --> 00:06:22.852 Which brings Felicia my son to

NOTE Confidence: 0.88896275

00:06:22.852 --> 00:06:25.410 the B cell positive for CD 22.

NOTE Confidence: 0.88896275

00:06:25.410 --> 00:06:26.302 After internalization,

NOTE Confidence: 0.88896275

00:06:26.302 --> 00:06:29.424 the drug is released inside the cell

NOTE Confidence: 0.88896275

00:06:29.424 --> 00:06:32.427 and code goes to the nucleus to cause

NOTE Confidence: 0.88896275

00:06:32.427 --> 00:06:34.697 cause DNA damage in a pop ptosis.

NOTE Confidence: 0.88896275

00:06:34.700 --> 00:06:37.059 Some of the drugs you can see

NOTE Confidence: 0.88896275

00:06:37.059 --> 00:06:38.070 can be flexed

NOTE Confidence: 0.78378654

00:06:38.151 --> 00:06:40.421 and circulating blood causing the

NOTE Confidence: 0.78378654

00:06:40.421 --> 00:06:43.354 main side effect of this medication

NOTE Confidence: 0.78378654

00:06:43.354 --> 00:06:46.229 in occlusive disease and deliver.

NOTE Confidence: 0.78378654

00:06:46.230 --> 00:06:48.862 So this study we as a Cancer Center

NOTE Confidence: 0.78378654

00:06:48.862 --> 00:06:50.829 participated in and contributed patients

NOTE Confidence: 0.78378654

00:06:50.829 --> 00:06:53.307 to innovate phase three study looked

NOTE Confidence: 0.78378654

00:06:53.307 --> 00:06:56.142 at the data some up again and relapse

NOTE Confidence: 0.78378654

00:06:56.142 --> 00:06:58.245 refractory B cell L patients including

NOTE Confidence: 0.78378654

00:06:58.245 --> 00:06:59.705 Peach posed accomplish negative

NOTE Confidence: 0.78378654

00:06:59.705 --> 00:07:01.564 and showed improved survival when

NOTE Confidence: 0.78378654

00:07:01.564 --> 00:07:03.339 compared to standard therapy group.

NOTE Confidence: 0.78378654

00:07:03.340 --> 00:07:06.070 So the median overall survival was 7.7

NOTE Confidence: 0.78378654

00:07:06.070 --> 00:07:08.624 versus 6.7 months and response rate was

NOTE Confidence: 0.78378654

00:07:08.624 --> 00:07:11.708 kind of double of what we see in Blender.

NOTE Confidence: 0.78378654

00:07:11.710 --> 00:07:13.924 Two map studies about 80% again

NOTE Confidence: 0.78378654

00:07:13.924 --> 00:07:16.288 with most of the patients 17%.

NOTE Confidence: 0.78378654

00:07:16.290 --> 00:07:17.928 Accomplishing negative minimal

NOTE Confidence: 0.78378654

00:07:17.928 --> 00:07:19.566 residual disease status.

NOTE Confidence: 0.78378654

00:07:19.570 --> 00:07:23.946 So today I'm going to talk about four

NOTE Confidence: 0.78378654

00:07:23.946 --> 00:07:27.620 studies and basically all of them.

NOTE Confidence: 0.78378654

00:07:27.620 --> 00:07:29.640 Are about adult patients with

NOTE Confidence: 0.78378654

00:07:29.640 --> 00:07:31.256 the introduction of drugs,

NOTE Confidence: 0.78378654

00:07:31.260 --> 00:07:34.200 which I used in relapse refractory setting

NOTE Confidence: 0.78378654

00:07:34.200 --> 00:07:37.318 in the frontline therapy for some of them.

NOTE Confidence: 0.78378654

00:07:37.320 --> 00:07:40.752 So we are trying to capitalize on the

NOTE Confidence: 0.78378654

00:07:40.752 --> 00:07:42.748 accomplishment and approval of this

NOTE Confidence: 0.78378654

00:07:42.748 --> 00:07:45.712 drugs and try to move them up front

NOTE Confidence: 0.78378654

00:07:45.712 --> 00:07:48.610 to get our patients to have better

NOTE Confidence: 0.78378654

00:07:48.610 --> 00:07:50.264 responses and ultimately survival.

NOTE Confidence: 0.78378654

00:07:50.264 --> 00:07:52.736 So the studies are grouped based

NOTE Confidence: 0.78378654

00:07:52.736 --> 00:07:55.282 on our approach to management of

NOTE Confidence: 0.78378654

00:07:55.282 --> 00:07:57.754 these patients and refers to wall.

NOTE Confidence: 0.78378654

00:07:57.760 --> 00:08:00.190 Look at the patient age and

NOTE Confidence: 0.78378654

00:08:00.190 --> 00:08:01.810 then Peach chromosome status,

NOTE Confidence: 0.78378654

00:08:01.810 --> 00:08:03.618 pH positive and pH.

NOTE Confidence: 0.78378654

00:08:03.618 --> 00:08:05.878 Negative patients are treated quite

NOTE Confidence: 0.78378654

00:08:05.878 --> 00:08:07.480 differently as you will see.

NOTE Confidence: 0.78378654

00:08:07.480 --> 00:08:10.824 So the first study is from MD Anderson

NOTE Confidence: 0.78378654

00:08:10.824 --> 00:08:14.013 Cancer Center and I would like to thank

NOTE Confidence: 0.78378654

00:08:14.013 --> 00:08:16.813 all of the presenting authors who gave

NOTE Confidence: 0.78378654

00:08:16.813 --> 00:08:20.035 me their slides to share with you today.

NOTE Confidence: 0.78378654

00:08:20.035 --> 00:08:22.870 So the first study is about pH,

NOTE Confidence: 0.78378654

00:08:22.870 --> 00:08:25.630 negative B cell L adults who were treated

NOTE Confidence: 0.78378654

00:08:25.630 --> 00:08:28.508 with Hyper Civitan sequential blinatumomab.

NOTE Confidence: 0.78378654

00:08:28.510 --> 00:08:30.328 And again, the speech negative patients.

NOTE Confidence: 0.78378654

00:08:30.330 --> 00:08:32.778 So let's have a look at the results of

NOTE Confidence: 0.78378654

00:08:32.778 --> 00:08:35.195 this phase two study from MD Anderson.

NOTE Confidence: 0.78378654

00:08:35.200 --> 00:08:37.216 So the primary endpoint of the study was

NOTE Confidence: 0.78378654

00:08:37.216 --> 00:08:39.150 relapse free survival secondary endpoints.

NOTE Confidence: 0.78378654

00:08:39.150 --> 00:08:41.530 You can look at here including overall

NOTE Confidence: 0.78378654

00:08:41.530 --> 00:08:43.829 response rate and MRD negativity rate.

NOTE Confidence: 0.78378654

00:08:43.830 --> 00:08:45.690 So this you are newly

NOTE Confidence: 0.78378654

00:08:45.690 --> 00:08:47.178 diagnosed patients with pH,

NOTE Confidence: 0.78378654

00:08:47.180 --> 00:08:48.188 negative B cell,

NOTE Confidence: 0.78378654

00:08:48.188 --> 00:08:50.204 LL patients could receive one cycle

NOTE Confidence: 0.78378654

00:08:50.204 --> 00:08:52.387 induction chemotherapy prior to enrollment.

NOTE Confidence: 0.78378654

00:08:52.390 --> 00:08:55.216 Of course they have to get to MD Anderson

NOTE Confidence: 0.78378654

00:08:55.216 --> 00:08:57.590 from elsewhere where they treated.

NOTE Confidence: 0.78378654

00:08:57.590 --> 00:09:00.250 So that's why they kind of broaden

NOTE Confidence: 0.78378654

00:09:00.250 --> 00:09:02.060 the inclusion criteria this way.

NOTE Confidence: 0.78378654

00:09:02.060 --> 00:09:02.431 Interestingly,

NOTE Confidence: 0.78378654

00:09:02.431 --> 00:09:05.028 they included patients age 14 and older,

NOTE Confidence: 0.78378654

14

00:09:05.030 --> 00:09:07.382 so this is usually going in the

NOTE Confidence: 0.78378654

00:09:07.382 --> 00:09:09.499 territory where Nina treats patients,

NOTE Confidence: 0.78378654

00:09:09.500 --> 00:09:12.068 so they allowed enrollment of younger

NOTE Confidence: 0.78378654

00:09:12.068 --> 00:09:14.870 patients on the study this patients.

NOTE Confidence: 0.78378654

00:09:14.870 --> 00:09:17.360 Have to be eligible for intensive

NOTE Confidence: 0.78378654

00:09:17.360 --> 00:09:17.775 chemotherapy.

NOTE Confidence: 0.78378654

00:09:17.780 --> 00:09:19.785 Equal Performance status of three

NOTE Confidence: 0.78378654

00:09:19.785 --> 00:09:21.790 or less adequate organ function

NOTE Confidence: 0.78378654

00:09:21.858 --> 00:09:24.018 and no significant CNS involvement.

NOTE Confidence: 0.78378654

00:09:24.020 --> 00:09:26.100 So CNS patients patient was

NOTE Confidence: 0.78378654

00:09:26.100 --> 00:09:28.180 seen as leukemia were excluded,

NOTE Confidence: 0.78378654

00:09:28.180 --> 00:09:31.508 so this is the schema of the study.

NOTE Confidence: 0.78378654

00:09:31.510 --> 00:09:34.422 You can see this is 4 cycles

NOTE Confidence: 0.78378654

00:09:34.422 --> 00:09:36.502 of hyper seaward, part A&B,

NOTE Confidence: 0.78378654

00:09:36.502 --> 00:09:39.830 with addition of Rituxan two patients for CD,

NOTE Confidence: 0.78378654

00:09:39.830 --> 00:09:43.036 20 positive or over to map another

15

NOTE Confidence: 0.78378654

00:09:43.036 --> 00:09:44.410 CD 20 antibody.

NOTE Confidence: 0.78378654

00:09:44.410 --> 00:09:46.993 As well as use of prophylactic it

NOTE Confidence: 0.78378654

00:09:46.993 --> 00:09:48.850 chemotherapy sectarian metrics 8 so

NOTE Confidence: 0.78378654

00:09:48.850 --> 00:09:50.580 after finishing this intensive phase,

NOTE Confidence: 0.78378654

00:09:50.580 --> 00:09:52.596 patients would go to blender two

NOTE Confidence: 0.78378654

00:09:52.596 --> 00:09:54.790 more phase where they would receive

NOTE Confidence: 0.78378654

00:09:54.790 --> 00:09:56.745 6 four cycles of blinatumomab,

NOTE Confidence: 0.74640524

00:09:56.750 --> 00:09:58.570 four weeks on continuous infusion,

NOTE Confidence: 0.74640524

00:09:58.570 --> 00:10:00.146 two weeks off and.

NOTE Confidence: 0.74640524

00:10:00.146 --> 00:10:02.116 Go to maintenance phase which

NOTE Confidence: 0.74640524

00:10:02.116 --> 00:10:04.956 is actually 18 as opposed to 36

NOTE Confidence: 0.74640524

00:10:04.956 --> 00:10:07.929 months and the blender two map is

NOTE Confidence: 0.74640524

00:10:07.929 --> 00:10:10.557 incorporated between the cycles of pomp,

NOTE Confidence: 0.74640524

00:10:10.560 --> 00:10:11.814 chemotherapy and additional

NOTE Confidence: 0.74640524

00:10:11.814 --> 00:10:13.486 3 cycles of blinatumomab.

NOTE Confidence: 0.74640524

00:10:13.490 --> 00:10:15.580 As you can see here.

NOTE Confidence: 0.74640524

00:10:15.580 --> 00:10:18.394 So these are the patients who were

NOTE Confidence: 0.74640524

00:10:18.394 --> 00:10:21.006 enrolled in the study, 38 patients.

NOTE Confidence: 0.74640524

00:10:21.006 --> 00:10:24.350 And as you can see the age difference.

NOTE Confidence: 0.74640524

00:10:24.350 --> 00:10:27.694 The H variance was between 17 and 59.

NOTE Confidence: 0.74640524

00:10:27.700 --> 00:10:30.997 The patients about 32% of patients had.

NOTE Confidence: 0.74640524

00:10:31.000 --> 00:10:33.160 Adverse karyotype the pH like

NOTE Confidence: 0.74640524

00:10:33.160 --> 00:10:35.321 positive patients were 19% as

NOTE Confidence: 0.74640524

00:10:35.321 --> 00:10:37.907 defined by presence of CRLF 21.

NOTE Confidence: 0.74640524

00:10:37.910 --> 00:10:39.206 Flow cytometry testing,

NOTE Confidence: 0.74640524

00:10:39.206 --> 00:10:42.656 and 27% of patients get TP 53 mutation.

NOTE Confidence: 0.74640524

00:10:42.660 --> 00:10:45.900 So this is one of the secondary points

NOTE Confidence: 0.74640524

00:10:45.900 --> 00:10:48.630 response rates CR after induction was

NOTE Confidence: 0.74640524

00:10:48.630 --> 00:10:52.170 accomplished in 81% of patients and then yes,

NOTE Confidence: 0.74640524

00:10:52.170 --> 00:10:54.762 you know they preceded with Blender

NOTE Confidence: 0.74640524

00:10:54.762 --> 00:10:58.691 two Mob and at the end of 32 patients

NOTE Confidence: 0.74640524

00:10:58.691 --> 00:11:00.806 accomplished a CR and MRD,

NOTE Confidence: 0.74640524

00:11:00.810 --> 00:11:02.136 negativity was 71%.

NOTE Confidence: 0.74640524

00:11:02.136 --> 00:11:04.762 After induction and 97% at anytime

NOTE Confidence: 0.74640524

00:11:04.762 --> 00:11:06.040 during the study,

NOTE Confidence: 0.74640524

00:11:06.040 --> 00:11:08.890 early mortality was at 0.

NOTE Confidence: 0.74640524

00:11:08.890 --> 00:11:09.310 So.

NOTE Confidence: 0.74640524

00:11:09.310 --> 00:11:10.570 I relapse free.

NOTE Confidence: 0.74640524

00:11:10.570 --> 00:11:13.697 Survival was not one of the endpoints

NOTE Confidence: 0.74640524

00:11:13.697 --> 00:11:17.090 of the study, and as you can see,

NOTE Confidence: 0.74640524

00:11:17.090 --> 00:11:20.050 relapse free survival at two years is 71%.

NOTE Confidence: 0.74640524

00:11:20.050 --> 00:11:21.196 At one year,

NOTE Confidence: 0.74640524

00:11:21.196 --> 00:11:24.490 80% overall survival was at two years of 80%,

NOTE Confidence: 0.74640524

00:11:24.490 --> 00:11:26.938 so it's pretty impressive numbers for

NOTE Confidence: 0.74640524

00:11:26.938 --> 00:11:29.298 patients for adults with B cell LL.

NOTE Confidence: 0.74640524

00:11:29.300 --> 00:11:32.569 Of course you know this particular group

NOTE Confidence: 0.74640524

00:11:32.569 --> 00:11:34.970 included younger patients 17 and older.

NOTE Confidence: 0.74640524

00:11:34.970 --> 00:11:37.376 So this is comparing the results

NOTE Confidence: 0.74640524

00:11:37.376 --> 00:11:39.986 of current study in blue with

NOTE Confidence: 0.74640524

00:11:39.986 --> 00:11:42.764 another study done in the same

NOTE Confidence: 0.74640524

00:11:42.764 --> 00:11:44.230 institution earlier hyper.

NOTE Confidence: 0.74640524

00:11:44.230 --> 00:11:47.016 See what with over to Mumbai think

NOTE Confidence: 0.74640524

00:11:47.016 --> 00:11:49.485 60 plus patient 69 patients and

NOTE Confidence: 0.74640524

00:11:49.485 --> 00:11:52.271 you can see that both studies show

NOTE Confidence: 0.74640524

00:11:52.352 --> 00:11:54.820 comperable to overall survival,

NOTE Confidence: 0.74640524

00:11:54.820 --> 00:11:57.214 but the plateau of no mortality

NOTE Confidence: 0.74640524

00:11:57.214 --> 00:11:59.885 after two years for the current

NOTE Confidence: 0.74640524

00:11:59.885 --> 00:12:01.869 study is very encouraging.

NOTE Confidence: 0.74640524

00:12:01.870 --> 00:12:04.140 So the side effects specifically

NOTE Confidence: 0.74640524

00:12:04.140 --> 00:12:05.956 adverse events of interest.

NOTE Confidence: 0.74640524

00:12:05.960 --> 00:12:07.910 Related to Blender two map

NOTE Confidence: 0.74640524

00:12:07.910 --> 00:12:09.470 highlighted in yellow side,

NOTE Confidence: 0.74640524

00:12:09.470 --> 00:12:12.851 The kind Release syndrome Grade 3 four

NOTE Confidence: 0.74640524

00:12:12.851 --> 00:12:16.170 was only seen in one patient and.

NOTE Confidence: 0.74640524

00:12:16.170 --> 00:12:18.726 It in your logical amounts were

NOTE Confidence: 0.74640524

00:12:18.726 --> 00:12:20.816 seen in 13% of patients.

NOTE Confidence: 0.74640524

00:12:20.816 --> 00:12:21.622 One patient,

NOTE Confidence: 0.74640524

00:12:21.622 --> 00:12:24.710 discontinued blended home up due to toxicity.

NOTE Confidence: 0.74640524

00:12:24.710 --> 00:12:27.699 It was great to encephalopathy and dysphasia,

NOTE Confidence: 0.74640524

00:12:27.700 --> 00:12:29.835 so the conclusion of this

NOTE Confidence: 0.74640524

00:12:29.835 --> 00:12:31.116 presentation is here.

NOTE Confidence: 0.74640524

00:12:31.120 --> 00:12:33.532 Hyper Squad with Sequential

NOTE Confidence: 0.74640524

00:12:33.532 --> 00:12:35.944 Blinatumomab is highly effective.

NOTE Confidence: 0.74640524

00:12:35.950 --> 00:12:38.242 Frontline therapy for pH negative deal

NOTE Confidence: 0.74640524

00:12:38.242 --> 00:12:40.928 adults, MRD rate was 97% year old,

NOTE Confidence: 0.74640524

00:12:40.930 --> 00:12:42.079 survival was 80%.

NOTE Confidence: 0.74640524

00:12:42.079 --> 00:12:44.760 There are no relapses beyond two years.

NOTE Confidence: 0.74640524

00:12:44.760 --> 00:12:47.273 There was low rate of grade three

NOTE Confidence: 0.74640524

00:12:47.273 --> 00:12:49.139 adverse events related to blinatumomab

NOTE Confidence: 0.74640524

00:12:49.139 --> 00:12:51.652 and at this time protocol is amended

NOTE Confidence: 0.74640524

00:12:51.652 --> 00:12:54.327 and now includes in autism observation.

NOTE Confidence: 0.74640524

00:12:54.330 --> 00:12:56.550 In addition to Blender tomorrow

NOTE Confidence: 0.74640524

00:12:56.550 --> 00:12:58.770 for frontline management of this

NOTE Confidence: 0.74640524

00:12:58.849 --> 00:13:03.619 group of patients. So the 2nd.

NOTE Confidence: 0.74640524

00:13:03.620 --> 00:13:04.824 Study or two studies.

NOTE Confidence: 0.74640524

00:13:04.824 --> 00:13:07.351 I would like to talk about our about

NOTE Confidence: 0.74640524

00:13:07.351 --> 00:13:08.981 older adults and the definition

NOTE Confidence: 0.74640524

00:13:08.981 --> 00:13:11.880 of all the adults in BLL world is

NOTE Confidence: 0.74640524

00:13:11.880 --> 00:13:13.360 different in different places.

NOTE Confidence: 0.74640524

00:13:13.360 --> 00:13:15.262 The first study again from this

NOTE Confidence: 0.74640524

00:13:15.262 --> 00:13:17.060 study is actually from Germany.

NOTE Confidence: 0.74640524

00:13:17.060 --> 00:13:19.316 German leukemia group and you know

NOTE Confidence: 0.74640524

00:13:19.316 --> 00:13:21.467 their definition of older adult was

NOTE Confidence: 0.74640524

00:13:21.467 --> 00:13:23.771 55 and older and then there will be.

NOTE Confidence: 0.74640524

00:13:23.780 --> 00:13:25.886 I will present results of meaning

NOTE Confidence: 0.74640524

00:13:25.886 --> 00:13:27.290 high perceived within autism

NOTE Confidence: 0.80523366

00:13:27.348 --> 00:13:29.160 up with or without Minotaur map.

NOTE Confidence: 0.80523366

00:13:29.160 --> 00:13:31.840 Here the definition is age 60 and older.

NOTE Confidence: 0.80523366

00:13:31.840 --> 00:13:34.199 So let's start from the German study.

NOTE Confidence: 0.80523366

00:13:34.200 --> 00:13:36.672 So this is. Initial one phase two trial

NOTE Confidence: 0.80523366

00:13:36.672 --> 00:13:38.516 which looked at induction treatment

NOTE Confidence: 0.80523366

00:13:38.516 --> 00:13:40.838 with three cycles of inotuzumab instead

NOTE Confidence: 0.80523366

00:13:40.838 --> 00:13:43.129 of regular chemotherapy induction,

NOTE Confidence: 0.80523366

00:13:43.130 --> 00:13:45.410 followed by standard to consolidate if

NOTE Confidence: 0.80523366

00:13:45.410 --> 00:13:47.320 approach from Journal Leukemia Group,

NOTE Confidence: 0.80523366

00:13:47.320 --> 00:13:50.370 which as you can see, is reasonably intense.

NOTE Confidence: 0.80523366

00:13:50.370 --> 00:13:51.890 Includes a asparaginase administration.

NOTE Confidence: 0.80523366

00:13:51.890 --> 00:13:53.800 It looks like 3 times.

NOTE Confidence: 0.80523366

00:13:53.800 --> 00:13:56.230 Also for CD 20 positive patients

00:13:56.230 --> 00:13:58.370 there is rituximab and so on.

00:13:58.370 --> 00:14:00.280 So this consolidation requires admission.

00:14:00.280 --> 00:14:02.872 And then there is about you know half

00:14:02.872 --> 00:14:05.759 of 6 MP methotrexate maintenance.

00:14:05.760 --> 00:14:09.320 Uh, so. The results,

00:14:09.320 --> 00:14:11.140 which were presented included

00:14:11.140 --> 00:14:12.505 mostly 31 patients,

00:14:12.510 --> 00:14:15.192 those who received at least one

00:14:15.192 --> 00:14:17.515 cycle Organism up induction and

00:14:17.515 --> 00:14:19.790 could be assessed for remission.

00:14:19.790 --> 00:14:22.495 So the patient characteristics table

00:14:22.495 --> 00:14:25.677 shows that patients which were enrolled

00:14:25.677 --> 00:14:28.837 were between 56 and 80 years old and

00:14:28.837 --> 00:14:32.198 you can see that all of these patients

00:14:32.198 --> 00:14:34.494 obviously had CD 22 expression.

NOTE Confidence: 0.80523366

00:14:34.494 --> 00:14:36.075 Different density of

NOTE Confidence: 0.80523366

00:14:36.075 --> 00:14:38.183 expression is represented here.

NOTE Confidence: 0.80523366

00:14:38.190 --> 00:14:38.926 So, uh,

NOTE Confidence: 0.80523366

00:14:38.926 --> 00:14:41.134 the secondary point end point of

NOTE Confidence: 0.80523366

00:14:41.134 --> 00:14:43.350 the study was response rates,

NOTE Confidence: 0.80523366

00:14:43.350 --> 00:14:46.614 and you can see that out 31 patients

NOTE Confidence: 0.80523366

00:14:46.614 --> 00:14:49.704 they looked at 100% had response CRCR I.

NOTE Confidence: 0.80523366

00:14:49.704 --> 00:14:52.520 And now this actually, you know,

NOTE Confidence: 0.80523366

00:14:52.520 --> 00:14:55.595 for patients receive three cycles.

NOTE Confidence: 0.80523366

00:14:55.600 --> 00:14:58.704 84% so some of them have their early

NOTE Confidence: 0.80523366

00:14:58.704 --> 00:15:01.735 relapses and there are no early deaths

NOTE Confidence: 0.80523366

00:15:01.735 --> 00:15:04.232 and then MRD was accomplished in

NOTE Confidence: 0.80523366

00:15:04.232 --> 00:15:06.480 78% of patients with this strategy.

NOTE Confidence: 0.80523366

00:15:06.480 --> 00:15:08.495 So there were some haematological

NOTE Confidence: 0.80523366

00:15:08.495 --> 00:15:09.704 and molecular responses.

NOTE Confidence: 0.80523366

00:15:09.710 --> 00:15:12.146 As you can see total of three

NOTE Confidence: 0.80523366

00:15:12.146 --> 00:15:14.162 and allogeneic stem transplant in

NOTE Confidence: 0.80523366

00:15:14.162 --> 00:15:16.850 remission was provided to three of

NOTE Confidence: 0.80523366

00:15:16.850 --> 00:15:19.409 those patients and one patient went

NOTE Confidence: 0.80523366

00:15:19.409 --> 00:15:21.797 to transplant after relapse so only

NOTE Confidence: 0.80523366

00:15:21.800 --> 00:15:23.408 four patients were transplanted

NOTE Confidence: 0.80523366

00:15:23.408 --> 00:15:25.956 out of this 31. So this is.

NOTE Confidence: 0.80523366

00:15:25.956 --> 00:15:28.140 The primary endpoint is on the right

NOTE Confidence: 0.80523366

00:15:28.214 --> 00:15:30.296 event free survival at one year,

NOTE Confidence: 0.80523366

00:15:30.300 --> 00:15:31.101 so was 87%.

NOTE Confidence: 0.80523366

00:15:31.101 --> 00:15:32.970 So for all the group of patients

NOTE Confidence: 0.80523366

00:15:33.034 --> 00:15:35.074 is actually pretty good and then

NOTE Confidence: 0.80523366

00:15:35.074 --> 00:15:37.013 overall survival at one year was

NOTE Confidence: 0.80523366

00:15:37.013 --> 00:15:38.601 also 87% events were defined,

NOTE Confidence: 0.80523366

00:15:38.601 --> 00:15:41.100 it persisting one marrable us after two

NOTE Confidence: 0.80523366

00:15:41.166 --> 00:15:43.670 cycles went into some of relapse or death.

NOTE Confidence: 0.80523366

00:15:43.670 --> 00:15:46.451 So this is a side effects are in relation

NOTE Confidence: 0.80523366

00:15:46.451 --> 00:15:49.159 to inductions within a two zone map.

NOTE Confidence: 0.80523366

00:15:49.160 --> 00:15:50.996 As you can see after initial

NOTE Confidence: 0.80523366

00:15:50.996 --> 00:15:52.930 induction that are more cytopenias.

NOTE Confidence: 0.80523366

00:15:52.930 --> 00:15:55.352 But you know this kind of decreases

NOTE Confidence: 0.80523366

00:15:55.352 --> 00:15:56.779 overtime obviously and then

NOTE Confidence: 0.80523366

00:15:56.779 --> 00:15:58.419 the side effect of interest.

NOTE Confidence: 0.80523366

00:15:58.420 --> 00:16:00.712 Here adverse event of interest would

NOTE Confidence: 0.80523366

00:16:00.712 --> 00:16:02.606 be LFT abnormalities because we

NOTE Confidence: 0.80523366

00:16:02.606 --> 00:16:04.436 inclusive disease is one of those

NOTE Confidence: 0.80523366

00:16:04.436 --> 00:16:07.062 things we watch for and then some of

NOTE Confidence: 0.80523366

00:16:07.062 --> 00:16:08.707 treated patients and LFTS elevation

NOTE Confidence: 0.80523366

00:16:08.710 --> 00:16:10.768 were not common and no patients

NOTE Confidence: 0.80523366

00:16:10.768 --> 00:16:12.140 had been occlusive disease.

NOTE Confidence: 0.80523366

00:16:12.140 --> 00:16:13.460 Of course only four.

NOTE Confidence: 0.80523366

26

00:16:13.460 --> 00:16:15.977 Patients out of city one went to

NOTE Confidence: 0.80523366

00:16:15.977 --> 00:16:17.829 allogeneic stem cell transplant.

NOTE Confidence: 0.80523366

00:16:17.830 --> 00:16:19.867 The conclusion of the study in this

NOTE Confidence: 0.80523366

00:16:19.867 --> 00:16:22.552 map seems to be highly effective as

NOTE Confidence: 0.80523366

00:16:22.552 --> 00:16:24.300 monotherapy and using haematological

NOTE Confidence: 0.80523366

00:16:24.300 --> 00:16:26.607 remission in all patients with MRD

NOTE Confidence: 0.80523366

00:16:26.607 --> 00:16:28.692 accomplished in more than 70% of

NOTE Confidence: 0.80523366

00:16:28.692 --> 00:16:30.140 patients had acceptable toxicity.

NOTE Confidence: 0.80523366

00:16:30.140 --> 00:16:32.548 No early deaths observed.

NOTE Confidence: 0.80523366

00:16:32.548 --> 00:16:34.354 Novena occlusive disease.

NOTE Confidence: 0.80523366

00:16:34.360 --> 00:16:35.796 Promising survival 80% overall

NOTE Confidence: 0.80523366

00:16:35.796 --> 00:16:37.591 survival benefit survival at one

NOTE Confidence: 0.80523366

00:16:37.591 --> 00:16:39.758 year and finally another man has a

NOTE Confidence: 0.80523366

00:16:39.758 --> 00:16:41.325 great potential to become standard

NOTE Confidence: 0.80523366

00:16:41.325 --> 00:16:43.419 induction option in all the patients

NOTE Confidence: 0.80523366

00:16:43.419 --> 00:16:44.466 with newly diagnosed

NOTE Confidence: 0.7981414

00:16:44.470 --> 00:16:47.158 BLL. So we're not using this regiment at

NOTE Confidence: 0.7981414

00:16:47.158 --> 00:16:49.635 Yale, and I don't think it is frequently

NOTE Confidence: 0.7981414

00:16:49.635 --> 00:16:52.558 used in the United States, so we're kind

NOTE Confidence: 0.7981414

00:16:52.558 --> 00:16:54.574 of more interested in high perceived,

NOTE Confidence: 0.7981414

00:16:54.580 --> 00:16:57.212 which is of course the Backbone Regiment for

NOTE Confidence: 0.7981414

00:16:57.212 --> 00:16:59.639 MD Anderson Cancer Center and many hyper.

NOTE Confidence: 0.7981414

00:16:59.640 --> 00:17:01.590 See what is something we used

NOTE Confidence: 0.7981414

00:17:01.590 --> 00:17:03.340 in some patients over years?

NOTE Confidence: 0.7981414

00:17:03.340 --> 00:17:04.474 Older patients with?

NOTE Confidence: 0.7981414

00:17:04.474 --> 00:17:07.900 We sell LL as well as T cell LL.

NOTE Confidence: 0.7981414

00:17:07.900 --> 00:17:10.596 So I'm going to share with you the

NOTE Confidence: 0.7981414

00:17:10.596 --> 00:17:13.678 results of this mini high perceived study,

NOTE Confidence: 0.7981414

00:17:13.680 --> 00:17:16.200 which added in a tumor band later

NOTE Confidence: 0.7981414

00:17:16.200 --> 00:17:17.760 one blinatumomab for management

NOTE Confidence: 0.7981414

00:17:17.760 --> 00:17:20.220 of all the patients with Vissel.

NOTE Confidence: 0.7981414

28

00:17:20.220 --> 00:17:22.852 So here, ages 60 or more before

NOTE Confidence: 0.7981414

00:17:22.852 --> 00:17:24.840 on status up to three.

NOTE Confidence: 0.7981414

00:17:24.840 --> 00:17:26.632 Adequate organ function ejection

NOTE Confidence: 0.7981414

00:17:26.632 --> 00:17:29.320 fraction should be more than 40%.

NOTE Confidence: 0.7981414

00:17:29.320 --> 00:17:31.654 So those reduced so-called meaning hyper

NOTE Confidence: 0.7981414

00:17:31.654 --> 00:17:33.775 see what consists of cyclophosphamide

NOTE Confidence: 0.7981414

00:17:33.775 --> 00:17:35.684 reduced by 50% dexamethasone,

NOTE Confidence: 0.7981414

00:17:35.684 --> 00:17:37.380 again reduced by 50%.

NOTE Confidence: 0.7981414

00:17:37.380 --> 00:17:39.924 There is no under cycling metrics

NOTE Confidence: 0.7981414

00:17:39.924 --> 00:17:41.620 take high dose metrics,

NOTE Confidence: 0.7981414

00:17:41.620 --> 00:17:44.158 a reduced by 75% anhydrous site,

NOTE Confidence: 0.7981414

00:17:44.160 --> 00:17:45.435 urban by 83%.

NOTE Confidence: 0.7981414

00:17:45.435 --> 00:17:49.250 So the inner tubes mob was added one day,

NOTE Confidence: 0.7981414

00:17:49.250 --> 00:17:52.281 three for the first 4 courses and

NOTE Confidence: 0.7981414

00:17:52.281 --> 00:17:55.330 rituximab was used as usual on D2 and

NOTE Confidence: 0.7981414

00:17:55.330 --> 00:17:58.579 eight with four CD 20 positive patients.

NOTE Confidence: 0.7981414

00:17:58.580 --> 00:18:00.700 Patients already also received it.

NOTE Confidence: 0.7981414

00:18:00.700 --> 00:18:01.576 Chemotherapy prophylaxis.

NOTE Confidence: 0.7981414

00:18:01.576 --> 00:18:05.080 So this is the schema of the study.

NOTE Confidence: 0.7981414

00:18:05.080 --> 00:18:07.840 You can see that there are the eight

NOTE Confidence: 0.7981414

00:18:07.840 --> 00:18:09.857 cycles with it chemotherapy administered

NOTE Confidence: 0.7981414

00:18:09.857 --> 00:18:13.860 during the first 4 as well as in ministered.

NOTE Confidence: 0.7981414

00:18:13.860 --> 00:18:15.444 As I specified overtime,

NOTE Confidence: 0.7981414

00:18:15.444 --> 00:18:18.290 the dozing off into some other Wolf

NOTE Confidence: 0.7981414

00:18:18.290 --> 00:18:20.666 first six patients higher dose than

NOTE Confidence: 0.7981414

00:18:20.666 --> 00:18:23.439 those was like lower dose than hide.

NOTE Confidence: 0.7981414

00:18:23.440 --> 00:18:24.784 Those was escalated,

NOTE Confidence: 0.7981414

00:18:24.784 --> 00:18:28.354 and then finally at the end they settled

NOTE Confidence: 0.7981414

00:18:28.354 --> 00:18:31.900 on a dose of 1.3 on cycle one and one.

NOTE Confidence: 0.7981414

00:18:31.900 --> 00:18:33.001 On Cycle 2,

NOTE Confidence: 0.7981414

00:18:33.001 --> 00:18:33.368 four.

NOTE Confidence: 0.7981414

00:18:33.368 --> 00:18:35.570 So the study was further modified

NOTE Confidence: 0.7981414

00:18:35.651 --> 00:18:37.956 after enrollment of 49 patients,

NOTE Confidence: 0.7981414

00:18:37.960 --> 00:18:40.204 and here you can see that

NOTE Confidence: 0.7981414

00:18:40.204 --> 00:18:42.400 four out of eight cycles,

NOTE Confidence: 0.7981414

00:18:42.400 --> 00:18:45.228 we only have 4 cycles of chemotherapy.

NOTE Confidence: 0.7981414

00:18:45.230 --> 00:18:48.058 Now Inotuzumab is given twice per cycle,

NOTE Confidence: 0.7981414

00:18:48.060 --> 00:18:51.696 and the dozing is here and blender to map.

NOTE Confidence: 0.7981414

00:18:51.700 --> 00:18:54.563 4 cycles of blinatumomab I added in

NOTE Confidence: 0.7981414

00:18:54.563 --> 00:18:56.248 consolidation phase and maintenance

NOTE Confidence: 0.7981414

00:18:56.248 --> 00:18:58.534 was reduced from 36 months to

NOTE Confidence: 0.7981414

00:18:58.534 --> 00:19:01.124 18 months and now also includes

NOTE Confidence: 0.7981414

00:19:01.124 --> 00:19:02.948 four cycles of blinatumomab.

NOTE Confidence: 0.7981414

00:19:02.950 --> 00:19:03.985 So once again,

NOTE Confidence: 0.7981414

00:19:03.985 --> 00:19:06.055 this is starting from patient 50.

NOTE Confidence: 0.7981414

00:19:06.060 --> 00:19:07.785 An further total number of

NOTE Confidence: 0.7981414

00:19:07.785 --> 00:19:09.510 patients enrolled in this phase.

31

NOTE Confidence: 0.7981414

00:19:09.510 --> 00:19:11.230 Two trial with 70 patients.

NOTE Confidence: 0.7981414

00:19:11.230 --> 00:19:13.645 So 20 patients receive treatment this way.

NOTE Confidence: 0.7981414

00:19:13.650 --> 00:19:16.058 So this is characteristics of the patients.

NOTE Confidence: 0.7981414

00:19:16.060 --> 00:19:18.922 And as you can see that you know these

NOTE Confidence: 0.7981414

00:19:18.922 --> 00:19:21.530 are all the patients 6281 and there

NOTE Confidence: 0.7981414

00:19:21.530 --> 00:19:24.340 are 41% of them are 70 or older.

NOTE Confidence: 0.7981414

00:19:24.340 --> 00:19:26.776 The complex karyotype as well as other

NOTE Confidence: 0.7981414

00:19:26.776 --> 00:19:28.202 cytogenetic abnormalities which I

NOTE Confidence: 0.7981414

00:19:28.202 --> 00:19:29.857 usually associate with worse outcomes.

NOTE Confidence: 0.7981414

00:19:29.860 --> 00:19:33.660 I seen in at least a third of those patients.

NOTE Confidence: 0.7981414

00:19:33.660 --> 00:19:36.243 As well as quite a few patients

NOTE Confidence: 0.7981414

00:19:36.243 --> 00:19:38.955 had that Peach like disease and

NOTE Confidence: 0.7981414

00:19:38.955 --> 00:19:40.479 TP53 mutated disease,

NOTE Confidence: 0.7981414

00:19:40.480 --> 00:19:43.455 so the overall response rate was 98%.

NOTE Confidence: 0.7981414

00:19:43.460 --> 00:19:44.669 This includes CR,

NOTE Confidence: 0.7981414

00:19:44.669 --> 00:19:48.140 CR P&CRI and there were no early deaths.

NOTE Confidence: 0.7981414

00:19:48.140 --> 00:19:51.974 MRD response on the 21 I was observed in

NOTE Confidence: 0.7981414

00:19:51.974 --> 00:19:55.389 78% and overall in 96% of the patients.

NOTE Confidence: 0.7981414

00:19:55.390 --> 00:19:57.940 So the reason that why numbers

NOTE Confidence: 0.7981414

00:19:57.940 --> 00:19:59.900 are all different, there's been.

NOTE Confidence: 0.7981414

00:19:59.900 --> 00:20:01.600 Five patients were enrolled in

NOTE Confidence: 0.7981414

00:20:01.600 --> 00:20:02.620 CR on this

NOTE Confidence: 0.812878906363636

00:20:02.688 --> 00:20:04.908 study. This is the patients who received

NOTE Confidence: 0.812878906363636

00:20:04.908 --> 00:20:06.740 one cycle before they were enrolled

NOTE Confidence: 0.812878906363636

00:20:06.740 --> 00:20:08.892 because they have to make it to MD

NOTE Confidence: 0.812878906363636

00:20:08.952 --> 00:20:10.857 Anderson to start their treatment.

NOTE Confidence: 0.812878906363636

00:20:10.860 --> 00:20:12.384 So these are grade three adverse

NOTE Confidence: 0.812878906363636

00:20:12.384 --> 00:20:14.288 events and I just highlighted here

NOTE Confidence: 0.812878906363636

00:20:14.288 --> 00:20:16.164 being occlusive disease, which was

NOTE Confidence: 0.812878906363636

00:20:16.164 --> 00:20:18.348 seen only in nine percent of patients.

NOTE Confidence: 0.83798635

00:20:20.360 --> 00:20:22.894 So this is the complete remission duration,

NOTE Confidence: 0.83798635

00:20:22.900 --> 00:20:25.078 which at three years was 79%.

NOTE Confidence: 0.83798635

00:20:25.080 --> 00:20:26.890 That's the top blue line.

NOTE Confidence: 0.83798635

00:20:26.890 --> 00:20:29.068 The Red line is overall survival

NOTE Confidence: 0.83798635

00:20:29.068 --> 00:20:30.808 line 56% at three years.

NOTE Confidence: 0.83798635

00:20:30.808 --> 00:20:33.160 Once again these are all the patients

NOTE Confidence: 0.83798635

00:20:33.229 --> 00:20:35.359 and there's a pretty good results

NOTE Confidence: 0.83798635

00:20:35.359 --> 00:20:37.420 for this population of patients.

NOTE Confidence: 0.83798635

00:20:37.420 --> 00:20:39.706 So this slide highlights worse outcomes

NOTE Confidence: 0.83798635

00:20:39.706 --> 00:20:42.139 in patients who are 70 and older.

NOTE Confidence: 0.83798635

00:20:42.140 --> 00:20:43.960 This is the blue line.

NOTE Confidence: 0.83798635

00:20:43.960 --> 00:20:45.612 As you can see,

NOTE Confidence: 0.83798635

00:20:45.612 --> 00:20:48.090 three azerate three year survival rate

NOTE Confidence: 0.83798635

00:20:48.171 --> 00:20:51.301 was 65 for patients who are 60 to 69 and.

NOTE Confidence: 0.83798635

00:20:51.310 --> 00:20:54.894 Only 43 for patients 470 and older.

NOTE Confidence: 0.83798635

00:20:54.900 --> 00:20:58.610 So I think you can see that.

NOTE Confidence: 0.83798635

00:20:58.610 --> 00:21:00.896 Conclusions are based on this results.

NOTE Confidence: 0.83798635

00:21:00.900 --> 00:21:02.800 Overall response rate was 98%

NOTE Confidence: 0.83798635

00:21:02.800 --> 00:21:04.324 margin negativity in 96%.

NOTE Confidence: 0.83798635

00:21:04.324 --> 00:21:06.229 There were no early deaths.

NOTE Confidence: 0.83798635

00:21:06.230 --> 00:21:08.140 3 SCR duration was 79.

NOTE Confidence: 0.83798635

00:21:08.140 --> 00:21:09.660 Overall survival of 56%.

NOTE Confidence: 0.83798635

00:21:09.660 --> 00:21:11.180 Best outcomes of course.

NOTE Confidence: 0.83798635

00:21:11.180 --> 00:21:13.956 In patients who are 60 to 69 and

NOTE Confidence: 0.83798635

00:21:13.956 --> 00:21:16.116 style studies now amended to

NOTE Confidence: 0.83798635

00:21:16.116 --> 00:21:17.960 eliminate chemotherapy for patients

NOTE Confidence: 0.83798635

00:21:17.960 --> 00:21:20.629 for 70 and older and older.

NOTE Confidence: 0.83798635

00:21:20.630 --> 00:21:22.544 A longer follow-up is of course

NOTE Confidence: 0.83798635

00:21:22.544 --> 00:21:24.838 needed to determine if a low dose

NOTE Confidence: 0.83798635

00:21:24.838 --> 00:21:26.433 fractionated into some oven blender

NOTE Confidence: 0.83798635

00:21:26.433 --> 00:21:28.608 to warm up will improve outcomes.

NOTE Confidence: 0.83798635

00:21:28.610 --> 00:21:30.908 So finally the last study is

NOTE Confidence: 0.83798635

00:21:30.908 --> 00:21:33.210 about pH positive DLL patients.

NOTE Confidence: 0.83798635

00:21:33.210 --> 00:21:36.963 Again, this is a study from MD Anderson Ann.

NOTE Confidence: 0.83798635

00:21:36.970 --> 00:21:39.189 Its interim results of the Phase 1

NOTE Confidence: 0.83798635

00:21:39.189 --> 00:21:41.646 two study of the Fanatic Phonetic

NOTE Confidence: 0.83798635

00:21:41.646 --> 00:21:43.562 locks and dexamethasone for

NOTE Confidence: 0.83798635

00:21:43.562 --> 00:21:46.190 patients with relapsed or refractory

NOTE Confidence: 0.83798635

00:21:46.190 --> 00:21:48.438 Philadelphia chromosome positive LL.

NOTE Confidence: 0.83798635

00:21:48.440 --> 00:21:49.436 So as you know,

NOTE Confidence: 0.83798635

00:21:49.436 --> 00:21:50.930 the never clocks is the drug

NOTE Confidence: 0.83798635

00:21:50.990 --> 00:21:53.310 which is currently approved for

NOTE Confidence: 0.83798635

00:21:53.310 --> 00:21:55.166 frontline treatment together with

NOTE Confidence: 0.83798635

00:21:55.166 --> 00:21:56.869 hyperventilating agents with FI LL

NOTE Confidence: 0.83798635

00:21:56.869 --> 00:21:58.633 also approved for treatment of CLL

NOTE Confidence: 0.83798635

00:21:58.640 --> 00:22:02.360 and so this is a BCL two inhibitor.

NOTE Confidence: 0.83798635

00:22:02.360 --> 00:22:04.649 So what is the logic of trying

NOTE Confidence: 0.83798635

00:22:04.649 --> 00:22:07.657 this drug in patients with DLL Now

NOTE Confidence: 0.83798635

00:22:07.657 --> 00:22:10.092 the outcomes of relapse refractory

NOTE Confidence: 0.83798635

00:22:10.092 --> 00:22:12.710 disease in Peach posted below poor.

NOTE Confidence: 0.83798635

00:22:12.710 --> 00:22:15.092 So the PACE trial showed that

NOTE Confidence: 0.83798635

00:22:15.092 --> 00:22:17.206 the native can induce responses

NOTE Confidence: 0.83798635

00:22:17.206 --> 00:22:20.220 and 40% of patients but one year

NOTE Confidence: 0.83798635

00:22:20.220 --> 00:22:22.650 progression free survival is only 8%.

NOTE Confidence: 0.83798635

00:22:22.650 --> 00:22:25.219 So pH positive LL is highly dependent

NOTE Confidence: 0.83798635

00:22:25.219 --> 00:22:28.235 on BCL two protein for its survival

NOTE Confidence: 0.83798635

00:22:28.235 --> 00:22:30.989 and that's why potentially there is

NOTE Confidence: 0.83798635

00:22:31.066 --> 00:22:33.820 a therapeutic role for phonetic lax.

NOTE Confidence: 0.83798635

00:22:33.820 --> 00:22:35.420 Preclinical studies also showed

NOTE Confidence: 0.83798635

00:22:35.420 --> 00:22:37.820 that platinum can cooperate with an

NOTE Confidence: 0.83798635

00:22:37.885 --> 00:22:40.069 attic locks and be synergistic in

NOTE Confidence: 0.83798635

00:22:40.069 --> 00:22:41.950 attacking Peach positive LL cells.

NOTE Confidence: 0.83798635

00:22:41.950 --> 00:22:44.659 So there is synergistic inhibition of growth.

NOTE Confidence: 0.83798635

00:22:44.660 --> 00:22:46.472 An induction of Opelousas,

NOTE Confidence: 0.83798635

00:22:46.472 --> 00:22:49.707 and perhaps the reason for it is

NOTE Confidence: 0.83798635

00:22:49.707 --> 00:22:52.759 inhibition of Lynn tires in Chinese by

NOTE Confidence: 0.83798635

00:22:52.759 --> 00:22:55.500 platinum and it increases beam and.

NOTE Confidence: 0.83798635

00:22:55.500 --> 00:22:58.038 Which prevents MCL one upregulation MCL.

NOTE Confidence: 0.83798635

00:22:58.040 --> 00:23:01.253 One is another anti up anti optic

NOTE Confidence: 0.83798635

00:23:01.253 --> 00:23:04.202 protein and usually in escape route

NOTE Confidence: 0.83798635

00:23:04.202 --> 00:23:07.660 when BCL two anti apoptosis is inhibited.

NOTE Confidence: 0.83798635

00:23:07.660 --> 00:23:09.556 So the results which were presented

NOTE Confidence: 0.83798635

00:23:09.556 --> 00:23:12.033 at ASH 2020 were results of the phase

NOTE Confidence: 0.83798635

00:23:12.033 --> 00:23:14.108 one of the study. Only nine patients.

NOTE Confidence: 0.83798635

00:23:14.108 --> 00:23:15.026 But you know,

NOTE Confidence: 0.83798635

00:23:15.030 --> 00:23:17.375 they are quite interesting and that's why

NOTE Confidence: 0.83798635

00:23:17.375 --> 00:23:19.908 I selected this for the discussion today.

NOTE Confidence: 0.83798635

00:23:19.910 --> 00:23:22.340 My so the point of Phase one studies of

NOTE Confidence: 0.83798635

00:23:22.340 --> 00:23:24.217 course to identify maximal tolerated

NOTE Confidence: 0.83798635

00:23:24.217 --> 00:23:26.539 dose of another class in combination

NOTE Confidence: 0.83798635

00:23:26.602 --> 00:23:28.478 with platinum and dexamethasone.

NOTE Confidence: 0.83798635

00:23:28.480 --> 00:23:30.265 There are secondary endpoint including

NOTE Confidence: 0.83798635

00:23:30.265 --> 00:23:32.050 CMR 8 Relapse free survival,

NOTE Confidence: 0.83798635

00:23:32.050 --> 00:23:34.283 overall survival and of course, safety.

NOTE Confidence: 0.83798635

00:23:34.283 --> 00:23:34.736 So.

NOTE Confidence: 0.83798635

00:23:34.736 --> 00:23:37.454 The patients who were included on

NOTE Confidence: 0.83798635

00:23:37.454 --> 00:23:38.360 the study

NOTE Confidence: 0.7313096

00:23:38.449 --> 00:23:40.625 where patients with relapsed

NOTE Confidence: 0.7313096

00:23:40.625 --> 00:23:43.345 refractory Peach positive LL with

NOTE Confidence: 0.7313096

00:23:43.345 --> 00:23:46.448 CML in lymphoid blah space and they

NOTE Confidence: 0.7313096

00:23:46.448 --> 00:23:49.756 have to be treated by at least one

NOTE Confidence: 0.7313096

00:23:49.756 --> 00:23:52.240 desireable TTI prior to the study.

NOTE Confidence: 0.7313096

00:23:52.240 --> 00:23:55.250 Age was 18 and older.

NOTE Confidence: 0.7313096

00:23:55.250 --> 00:23:56.366 Oclock performance status

NOTE Confidence: 0.7313096

00:23:56.366 --> 00:23:57.854 like in previous study.

NOTE Confidence: 0.7313096

00:23:57.860 --> 00:23:59.725 Adequate organ function nor uncontrolled

NOTE Confidence: 0.7313096

00:23:59.725 --> 00:24:00.844 active cardiovascular disease.

NOTE Confidence: 0.7313096

00:24:00.850 --> 00:24:03.088 Becausw Anatomy was known to have

NOTE Confidence: 0.7313096

00:24:03.088 --> 00:24:04.580 cardiovascular toxicity arterial occlusive,

NOTE Confidence: 0.7313096

00:24:04.580 --> 00:24:05.324 occlusive events,

NOTE Confidence: 0.7313096

00:24:05.324 --> 00:24:07.928 and no prior use of genetic lacks.

NOTE Confidence: 0.7313096

00:24:07.930 --> 00:24:10.914 So this is the schema of the study.

NOTE Confidence: 0.7313096

00:24:10.920 --> 00:24:11.292 Initially,

NOTE Confidence: 0.7313096

00:24:11.292 --> 00:24:14.268 patients were open at 9:45 for seven days,

NOTE Confidence: 0.7313096

00:24:14.270 --> 00:24:17.350 then the network locks ramp up together with

NOTE Confidence: 0.7313096

00:24:17.350 --> 00:24:19.870 dexamethasone for four days at 40 milligrams,

NOTE Confidence: 0.7313096

00:24:19.870 --> 00:24:21.735 so the phase one included

NOTE Confidence: 0.7313096

00:24:21.735 --> 00:24:23.600 ramping up to 400 milligrams,

NOTE Confidence: 0.7313096

00:24:23.600 --> 00:24:24.932 or 800 milligrams.

NOTE Confidence: 0.7313096

00:24:24.932 --> 00:24:26.708 So this were two.

NOTE Confidence: 0.7313096

00:24:26.710 --> 00:24:29.170 Those are some phonetic lacks which

NOTE Confidence: 0.7313096

00:24:29.170 --> 00:24:31.290 were accomplished in this study,

NOTE Confidence: 0.7313096

00:24:31.290 --> 00:24:33.072 so not new,

NOTE Confidence: 0.7313096

00:24:33.072 --> 00:24:36.636 but those was further reduced with.

NOTE Confidence: 0.7313096

00:24:36.640 --> 00:24:38.675 Haematological response to 30 milligrams

NOTE Confidence: 0.7313096

00:24:38.675 --> 00:24:40.710 and for patients with accomplished

NOTE Confidence: 0.7313096

00:24:40.774 --> 00:24:42.458 complete molecular response to.

NOTE Confidence: 0.7313096

00:24:42.460 --> 00:24:43.396 15 milligrams.

NOTE Confidence: 0.7313096

00:24:43.396 --> 00:24:46.204 To avoid arterial occlusive events and

NOTE Confidence: 0.7313096

00:24:46.204 --> 00:24:49.119 other side effects so as you can see,

NOTE Confidence: 0.7313096

00:24:49.120 --> 00:24:51.510 patients also received CNS prophylaxis

NOTE Confidence: 0.7313096

00:24:51.510 --> 00:24:55.118 and Rituxan if they were CD 20 positive.

NOTE Confidence: 0.7313096

00:24:55.120 --> 00:24:57.745 So this is the characteristic of this.

NOTE Confidence: 0.7313096

00:24:57.750 --> 00:25:00.000 Nine patients enrolled on this phase.

NOTE Confidence: 0.7313096

00:25:00.000 --> 00:25:02.821 One of the study you can see

NOTE Confidence: 0.7313096

00:25:02.821 --> 00:25:05.249 that the issue is 26 to 73.

NOTE Confidence: 0.7313096

00:25:05.250 --> 00:25:07.452 There were no patience with the

NOTE Confidence: 0.7313096

00:25:07.452 --> 00:25:09.370 with performance status of three,

NOTE Confidence: 0.7313096

00:25:09.370 --> 00:25:12.370 so half of the patients had T315I mutations.

NOTE Confidence: 0.7313096

00:25:12.370 --> 00:25:15.258 And as you can see it was very

NOTE Confidence: 0.7313096

00:25:15.258 --> 00:25:16.500 heavily pretreated group.

NOTE Confidence: 0.7313096

00:25:16.500 --> 00:25:18.435 17% order received platinum probably

NOTE Confidence: 0.7313096

00:25:18.435 --> 00:25:21.370 going to my treatment and 56% of patients

NOTE Confidence: 0.7313096

00:25:21.370 --> 00:25:23.988 and prior transplant in 67% of patients.

NOTE Confidence: 0.7313096

00:25:23.988 --> 00:25:26.202 So nine but very heavily pretreated

NOTE Confidence: 0.7313096

00:25:26.202 --> 00:25:28.670 patients with relapsed refractory disease.

NOTE Confidence: 0.7313096

00:25:28.670 --> 00:25:30.650 So we're not even look like

NOTE Confidence: 0.7313096

00:25:30.650 --> 00:25:32.484 Sundecks didn't cause any deal

NOTE Confidence: 0.7313096

00:25:32.484 --> 00:25:34.276 tease those limited toxicities.

NOTE Confidence: 0.7313096

00:25:34.280 --> 00:25:36.518 Maximal tolerated dose was not reached.

NOTE Confidence: 0.7313096

00:25:36.520 --> 00:25:38.450 Three patients were treated or

00:25:38.450 --> 00:25:40.380 magnetic locks 400 milligram those

00:25:40.441 --> 00:25:42.685 level one and six patients receive

00:25:42.685 --> 00:25:44.583 genetic lacks 800 milligrams and

00:25:44.583 --> 00:25:46.617 this was selected to be recommended.

00:25:46.620 --> 00:25:47.679 Phase two dose.

00:25:47.679 --> 00:25:49.797 There are no early mortality so

00:25:49.797 --> 00:25:52.226 the side effects are listed here.

00:25:52.230 --> 00:25:54.911 I think 1 interesting side effect in

00:25:54.911 --> 00:25:57.264 this storm Bolick event which occurred

00:25:57.264 --> 00:26:00.540 in one patient and was graded as Grade 3.

00:26:00.540 --> 00:26:02.196 Patient had DVT MP.

00:26:02.196 --> 00:26:04.266 There are patients who had

00:26:04.266 --> 00:26:06.667 great for Trump aside opinion,

00:26:06.670 --> 00:26:08.860 neutropenia but no febrile neutropenia.

00:26:08.860 --> 00:26:10.174 Not great four.

NOTE Confidence: 0.7313096

00:26:10.174 --> 00:26:11.488 So reasonably acceptable.

NOTE Confidence: 0.7313096

00:26:11.490 --> 00:26:13.470 Side effect profile for this

NOTE Confidence: 0.7313096

00:26:13.470 --> 00:26:15.054 heavily pretreated group of

NOTE Confidence: 0.7313096

00:26:15.054 --> 00:26:16.750 relapse refractory patients.

NOTE Confidence: 0.7313096

00:26:16.750 --> 00:26:19.366 So the response rate was 56%.

NOTE Confidence: 0.7313096

00:26:19.370 --> 00:26:20.246 Of course,

NOTE Confidence: 0.7313096

00:26:20.246 --> 00:26:22.874 it's five out of nine patients,

NOTE Confidence: 0.7313096

00:26:22.880 --> 00:26:27.260 44% of four now had CR and one had CR.

NOTE Confidence: 0.7313096

00:26:27.260 --> 00:26:28.362 I complete.

NOTE Confidence: 0.7313096

00:26:28.362 --> 00:26:30.566 Molecular response was accomplished.

NOTE Confidence: 0.7313096

00:26:30.570 --> 00:26:33.186 I'm on 4 out of nine patients and

NOTE Confidence: 0.7313096

00:26:33.186 --> 00:26:34.683 complete molecular response after

NOTE Confidence: 0.7313096

00:26:34.683 --> 00:26:36.999 first cycle was in three patients.

NOTE Confidence: 0.7313096

00:26:37.000 --> 00:26:38.960 One patient actually responded by

NOTE Confidence: 0.7313096

00:26:38.960 --> 00:26:40.528 decreasing blossom mirror from

NOTE Confidence: 0.7313096

44

00:26:40.528 --> 00:26:42.351 94 to 6% had neutrophil recovery

NOTE Confidence: 0.7313096

00:26:42.351 --> 00:26:43.779 in place with recovery,

NOTE Confidence: 0.7313096

00:26:43.780 --> 00:26:46.370 but was not counted as responded because

NOTE Confidence: 0.7313096

00:26:46.370 --> 00:26:49.002 Blacks were still about 5% in the marrow.

NOTE Confidence: 0.7313096

00:26:49.002 --> 00:26:51.200 So this is to highlight that phonetic

NOTE Confidence: 0.7313096

00:26:51.266 --> 00:26:53.076 likes those 800 milligram patients

NOTE Confidence: 0.7313096

00:26:53.076 --> 00:26:55.560 are the only patients who responded.

NOTE Confidence: 0.7313096

00:26:55.560 --> 00:26:57.410 None of the three patients

NOTE Confidence: 0.7313096

00:26:57.410 --> 00:26:59.260 who received an attic LAX

NOTE Confidence: 0.8183674

00:26:59.341 --> 00:27:02.717 at 400. Those responded, but five out of 6.

NOTE Confidence: 0.8183674

00:27:02.720 --> 00:27:05.247 Our patients in those two with 800

NOTE Confidence: 0.8183674

00:27:05.247 --> 00:27:07.630 milligrams of another class had response,

NOTE Confidence: 0.8183674

00:27:07.630 --> 00:27:10.276 so this is of course 9 patients.

NOTE Confidence: 0.8183674

00:27:10.280 --> 00:27:11.788 Potassium plus fanatical X

NOTE Confidence: 0.8183674

00:27:11.788 --> 00:27:13.667 one year old survival, 63%.

NOTE Confidence: 0.8183674

00:27:13.667 --> 00:27:16.236 Only two patients died and those were

NOTE Confidence: 0.8183674

00:27:16.236 --> 00:27:18.598 nonresponders they were not relapse patients.

NOTE Confidence: 0.8183674

00:27:18.600 --> 00:27:20.924 They did not respond to the magnet

NOTE Confidence: 0.8183674

00:27:20.924 --> 00:27:22.750 and Venetic lacks combination.

NOTE Confidence: 0.8183674

00:27:22.750 --> 00:27:24.916 And as you can see this

NOTE Confidence: 0.8183674

00:27:24.916 --> 00:27:26.910 is six months or less.

NOTE Confidence: 0.8183674

00:27:26.910 --> 00:27:29.178 3 survival of 100% for five

NOTE Confidence: 0.8183674

00:27:29.178 --> 00:27:30.690 patients is reasonably reassuring.

NOTE Confidence: 0.8183674

00:27:30.690 --> 00:27:34.623 You once again it's a small phase one study.

NOTE Confidence: 0.8183674

00:27:34.630 --> 00:27:35.659 So in conclusion,

NOTE Confidence: 0.8183674

00:27:35.659 --> 00:27:37.717 this is oral regimen of banana

NOTE Confidence: 0.8183674

00:27:37.717 --> 00:27:39.570 phonetic likes and dexamethasone,

NOTE Confidence: 0.8183674

00:27:39.570 --> 00:27:41.850 and this looks like safe and

NOTE Confidence: 0.8183674

00:27:41.850 --> 00:27:43.370 effective in heavily pretreated,

NOTE Confidence: 0.8183674

00:27:43.370 --> 00:27:44.510 relapsed refractory Peach

NOTE Confidence: 0.8183674

00:27:44.510 --> 00:27:45.650 post available patients.

NOTE Confidence: 0.8183674

00:27:45.650 --> 00:27:47.930 Maximal tolerated dose was not reached,

NOTE Confidence: 0.8183674

00:27:47.930 --> 00:27:50.975 and those selected for phase two of

NOTE Confidence: 0.8183674

00:27:50.975 --> 00:27:54.297 this study is 800 MG CR CR rate was

NOTE Confidence: 0.8183674

00:27:54.297 --> 00:27:56.670 56 on CMR rate was 44% responses

NOTE Confidence: 0.8183674

00:27:56.670 --> 00:27:58.190 were observed across subgroups,

NOTE Confidence: 0.8183674

00:27:58.190 --> 00:28:00.850 but may be high in Veneta clocks.

NOTE Confidence: 0.8183674

00:28:00.850 --> 00:28:03.130 800 milligram daily Group estimated one

NOTE Confidence: 0.8183674

00:28:03.130 --> 00:28:05.865 year old survival 63% no relapses today.

NOTE Confidence: 0.8183674

00:28:05.865 --> 00:28:07.080 Correlative studies ongoing

NOTE Confidence: 0.8183674

00:28:07.080 --> 00:28:08.700 to better understand mechanism

NOTE Confidence: 0.8183674

00:28:08.758 --> 00:28:10.178 of response and resistance.

NOTE Confidence: 0.8183674

00:28:10.180 --> 00:28:13.673 So what do we do with yell

NOTE Confidence: 0.8183674

00:28:13.673 --> 00:28:16.419 to introduce this new drugs?

NOTE Confidence: 0.8183674

00:28:16.420 --> 00:28:18.015 Our two frontline management of

NOTE Confidence: 0.8183674

00:28:18.015 --> 00:28:20.359 our patients so we are opening this

NOTE Confidence: 0.8183674

00:28:20.359 --> 00:28:22.074 alliance study phase two trial

NOTE Confidence: 0.8183674

00:28:22.074 --> 00:28:23.990 overnight as a mob induction,

NOTE Confidence: 0.8183674

00:28:23.990 --> 00:28:25.958 followed by Glenna to map consolidation

NOTE Confidence: 0.8183674

00:28:25.958 --> 00:28:27.690 for patients with newly diagnosed

NOTE Confidence: 0.8183674

00:28:27.690 --> 00:28:29.146 or relapse refractory CD.

NOTE Confidence: 0.8183674

00:28:29.150 --> 00:28:30.430 22 points of DLL.

NOTE Confidence: 0.8183674

00:28:30.430 --> 00:28:33.876 I have to say that CD 19 and CD 22

NOTE Confidence: 0.8183674

00:28:33.876 --> 00:28:36.042 positivity is seen in more than

NOTE Confidence: 0.8183674

00:28:36.124 --> 00:28:37.854 90% of patients with SLE,

NOTE Confidence: 0.8183674

00:28:37.854 --> 00:28:40.080 so this cohort one includes patients

NOTE Confidence: 0.8183674

00:28:40.148 --> 00:28:42.500 older than 60 and older and we will

NOTE Confidence: 0.8183674

00:28:42.500 --> 00:28:44.629 be looking at event free survival,

NOTE Confidence: 0.8183674

00:28:44.630 --> 00:28:46.206 one event free survival.

NOTE Confidence: 0.8183674

00:28:46.206 --> 00:28:48.176 For this transplant in eligible

NOTE Confidence: 0.8183674

00:28:48.176 --> 00:28:50.489 patient group with newly diagnosed LL,

NOTE Confidence: 0.8183674

00:28:50.490 --> 00:28:52.524 the cohort two is for younger

NOTE Confidence: 0.8183674

00:28:52.524 --> 00:28:54.336 patients who have relapsed refractory

NOTE Confidence: 0.8183674

00:28:54.336 --> 00:28:55.888 disease and you know,

NOTE Confidence: 0.8183674

00:28:55.890 --> 00:28:57.984 of course this patients potentially can

NOTE Confidence: 0.8183674

00:28:57.984 --> 00:29:00.569 go to transplant if they have response.

NOTE Confidence: 0.8183674

00:29:00.570 --> 00:29:02.370 So this combination makes sense

NOTE Confidence: 0.8183674

00:29:02.370 --> 00:29:04.170 because of the existing vanity.

NOTE Confidence: 0.8183674

00:29:04.170 --> 00:29:06.174 Zoom up within occlusive disease post

NOTE Confidence: 0.8183674

00:29:06.174 --> 00:29:08.130 transplant and even without transplant.

NOTE Confidence: 0.8183674

00:29:08.130 --> 00:29:10.419 And that's why we would like to

NOTE Confidence: 0.8183674

00:29:10.419 --> 00:29:12.247 separate transplant by giving other

NOTE Confidence: 0.8183674

00:29:12.247 --> 00:29:14.605 treatments to this patients in between.

NOTE Confidence: 0.8183674

00:29:14.610 --> 00:29:16.470 Another modern transplant itself.

NOTE Confidence: 0.8183674

00:29:16.470 --> 00:29:20.544 So I would like to wrap it up at

NOTE Confidence: 0.8183674

00:29:20.544 --> 00:29:22.938 this point and next speaker doctor,

NOTE Confidence: 0.8183674

00:29:22.940 --> 00:29:23.342 Nina,

NOTE Confidence: 0.8183674

00:29:23.342 --> 00:29:25.754 Kate and Logic will be talking

NOTE Confidence: 0.8183674

00:29:25.754 --> 00:29:27.610 about pediatric AOL studies.

NOTE Confidence: 0.7874477

00:29:38.910 --> 00:29:40.774 You know, now you have to share your

NOTE Confidence: 0.7874477

00:29:40.774 --> 00:29:43.530 slides. I just unshared. Thank you.

NOTE Confidence: 0.8930809

00:29:56.700 --> 00:29:57.768 So thank you,

NOTE Confidence: 0.8930809

00:29:57.768 --> 00:30:00.260 I'm going to now shift the focus.

NOTE Confidence: 0.8930809

00:30:00.260 --> 00:30:02.740 Two childhood adolescent and young

NOTE Confidence: 0.8930809

00:30:02.740 --> 00:30:05.812 adult ELL and I'm including young

NOTE Confidence: 0.8930809

00:30:05.812 --> 00:30:08.372 adult because often the eligibility

NOTE Confidence: 0.8930809

00:30:08.372 --> 00:30:11.368 for our studies extend well into

NOTE Confidence: 0.8930809

00:30:11.368 --> 00:30:13.538 the 20s and sometimes older.

NOTE Confidence: 0.83558816

00:30:16.440 --> 00:30:21.020 So I'm going to focus most of my time on

NOTE Confidence: 0.83558816

00:30:21.139 --> 00:30:26.018 the 1st three abstracts. The first is our.

NOTE Confidence: 0.8058765

00:30:29.110 --> 00:30:31.978 Presented the results of our recently

NOTE Confidence: 0.8058765

00:30:31.978 --> 00:30:34.630 closed T cell lymphoblastic leukemia.

NOTE Confidence: 0.8058765

00:30:34.630 --> 00:30:37.948 Lymphoma study AALL 1231 in which Pertuzumab

NOTE Confidence: 0.8058765

00:30:37.948 --> 00:30:41.044 was studied and which cranial radiation

NOTE Confidence: 0.8058765

00:30:41.044 --> 00:30:44.144 was illuminated for 90% of patients.

NOTE Confidence: 0.8058765

00:30:44.144 --> 00:30:47.553 Next, I'm going to discuss results of

NOTE Confidence: 0.8058765

00:30:47.553 --> 00:30:50.660 using Blue Netuma map versus intensive

NOTE Confidence: 0.8058765

00:30:50.660 --> 00:30:53.710 chemo in children in high risk.

NOTE Confidence: 0.8058765

00:30:53.710 --> 00:30:57.406 First, relapse of B cell LL.

NOTE Confidence: 0.8058765

00:30:57.410 --> 00:31:00.518 Anne, and then I'm going to

NOTE Confidence: 0.8058765

00:31:00.518 --> 00:31:02.590 discuss some results regarding

NOTE Confidence: 0.8058765

00:31:02.687 --> 00:31:05.368 the prior use of Luna to mmap.

NOTE Confidence: 0.8058765

00:31:05.370 --> 00:31:11.090 As associated with karty outcomes.

NOTE Confidence: 0.8058765

00:31:11.090 --> 00:31:13.866 And then I'm going to shift and talk

NOTE Confidence: 0.8058765

00:31:13.866 --> 00:31:16.594 a bit about toxicity related to

NOTE Confidence: 0.8058765

00:31:16.594 --> 00:31:20.185 asparagine ease and maybe some of the

NOTE Confidence: 0.8058765

00:31:20.185 --> 00:31:23.075 factors associated with that toxicity.

NOTE Confidence: 0.8309488

00:31:27.970 --> 00:31:31.394 The first study is by the study chair,

NOTE Confidence: 0.8309488

51

00:31:31.400 --> 00:31:33.842 Doctor Teachey and I would like

NOTE Confidence: 0.8309488

00:31:33.842 --> 00:31:36.549 to also thank all the authors,

NOTE Confidence: 0.8309488

00:31:36.550 --> 00:31:40.696 investigators who slides I will present.

NOTE Confidence: 0.8309488

00:31:40.700 --> 00:31:43.820 And this is a ALL 1231.

NOTE Confidence: 0.8309488

00:31:43.820 --> 00:31:47.396 The reason that there is a

NOTE Confidence: 0.8309488

00:31:47.396 --> 00:31:50.850 T allow study even though.

NOTE Confidence: 0.8309488

00:31:50.850 --> 00:31:53.160 Three year event free survival

NOTE Confidence: 0.8309488

00:31:53.160 --> 00:31:55.942 approaches 90% is that T cell

NOTE Confidence: 0.8309488

00:31:55.942 --> 00:31:58.257 patients can't really be salvage.

NOTE Confidence: 0.8309488

00:31:58.260 --> 00:32:02.244 They have really. Abysmal outcomes.

NOTE Confidence: 0.8309488

00:32:02.244 --> 00:32:07.038 If they relapse, so the goal is to try

NOTE Confidence: 0.8309488

00:32:07.038 --> 00:32:11.750 to treat them up front as much as possible.

NOTE Confidence: 0.8309488

00:32:11.750 --> 00:32:15.230 So part is Amab is a proteasome inhibitor.

NOTE Confidence: 0.8309488

00:32:15.230 --> 00:32:19.045 It inhibits Dave teaching would call it

NOTE Confidence: 0.8309488

00:32:19.045 --> 00:32:23.168 the garbage can of the cell it inhibits.

NOTE Confidence: 0.8309488

00:32:23.170 --> 00:32:25.788 And is supposed to be pretty old.

NOTE Confidence: 0.8309488

00:32:25.790 --> 00:32:27.620 Zones are supposed to take

NOTE Confidence: 0.8309488

00:32:27.620 --> 00:32:29.900 care of waste from the cell.

NOTE Confidence: 0.8309488

00:32:29.900 --> 00:32:31.392 Inhibitors inhibit a number

NOTE Confidence: 0.8309488

00:32:31.392 --> 00:32:32.884 of the regulatory proteins,

NOTE Confidence: 0.8309488

00:32:32.890 --> 00:32:33.895 including NF KB,

NOTE Confidence: 0.8309488

00:32:33.895 --> 00:32:35.905 which is very important in T

NOTE Confidence: 0.8309488

00:32:35.905 --> 00:32:37.380 cell LL pathogenesis.

NOTE Confidence: 0.8309488

00:32:37.380 --> 00:32:39.930 It's been shown in relapse studies

NOTE Confidence: 0.8309488

00:32:39.930 --> 00:32:42.790 to be well tolerated and effective.

NOTE Confidence: 0.8309488

00:32:42.790 --> 00:32:45.766 So therefore it was the basis of this

NOTE Confidence: 0.8309488

00:32:45.766 --> 00:32:49.867 study and the Burtis amab is an upfront

NOTE Confidence: 0.8309488

00:32:49.867 --> 00:32:52.051 randomization randomization that starts

NOTE Confidence: 0.8309488

00:32:52.134 --> 00:32:54.269 an induction and those randomized

NOTE Confidence: 0.8309488

00:32:54.269 --> 00:32:57.871 get a total of eight doses of autism.

NOTE Confidence: 0.8309488

00:32:57.871 --> 00:33:00.306 The induction backbone changed for

NOTE Confidence: 0.8309488

00:33:00.306 --> 00:33:03.446 TLL compared to past studies in a

NOTE Confidence: 0.8309488

00:33:03.446 --> 00:33:05.536 nonrandomized way based on British

NOTE Confidence: 0.8309488

00:33:05.617 --> 00:33:08.263 data in which all patients get

NOTE Confidence: 0.8309488

00:33:08.263 --> 00:33:10.958 dexamethasone and two doses of peg.

NOTE Confidence: 0.8309488

00:33:10.958 --> 00:33:13.278 Asparagine, Ace, and then randomization.

NOTE Confidence: 0.8309488

00:33:13.280 --> 00:33:17.718 Is based on end of consolidation MRD.

NOTE Confidence: 0.8309488

00:33:17.720 --> 00:33:20.842 So one is classified as standard res

NOTE Confidence: 0.8309488

00:33:20.842 --> 00:33:23.438 intermediate risk or very high risk.

NOTE Confidence: 0.8309488

00:33:23.440 --> 00:33:26.373 Based on that and the backbone very

NOTE Confidence: 0.8309488

00:33:26.373 --> 00:33:29.082 slightly in terms of the intensive

NOTE Confidence: 0.8309488

00:33:29.082 --> 00:33:31.357 therapy based on risk status.

NOTE Confidence: 0.8309488

00:33:31.360 --> 00:33:34.414 The only group that gets radiation

NOTE Confidence: 0.8309488

00:33:34.414 --> 00:33:37.929 are the very high risk patients.

NOTE Confidence: 0.8309488

00:33:37.930 --> 00:33:40.667 For those who are seen as positive

NOTE Confidence: 0.8309488

00:33:40.667 --> 00:33:41.449 at diagnosis,

NOTE Confidence: 0.8309488

00:33:41.450 --> 00:33:43.628 90% of patients do not get

NOTE Confidence: 0.8309488

00:33:43.628 --> 00:33:45.750 radiation and this was decided.

NOTE Confidence: 0.8309488

00:33:45.750 --> 00:33:48.298 And that was one of the decisions

NOTE Confidence: 0.8309488

00:33:48.298 --> 00:33:49.879 for using dexamethasone induction

NOTE Confidence: 0.8309488

00:33:49.879 --> 00:33:52.399 because of the tire CNS penetration.

NOTE Confidence: 0.8309488

00:33:52.400 --> 00:33:55.095 There was a great goal in our

NOTE Confidence: 0.8309488

00:33:55.095 --> 00:33:57.500 group because of the high cure

NOTE Confidence: 0.8309488

00:33:57.500 --> 00:33:59.435 rates in the long term.

NOTE Confidence: 0.8309488

00:33:59.440 --> 00:34:01.390 Late effects to try to

NOTE Confidence: 0.8309488

00:34:01.390 --> 00:34:02.950 eliminate this this radiation.

NOTE Confidence: 0.8259487

00:34:05.900 --> 00:34:08.060 The T lymphoblastic lymphoma patients

NOTE Confidence: 0.8259487

00:34:08.060 --> 00:34:10.706 were also eligible for this study

NOTE Confidence: 0.8259487

00:34:10.706 --> 00:34:12.756 and their end of consolidation.

NOTE Confidence: 0.8259487

00:34:12.760 --> 00:34:15.416 MRD was based on Image Ng and I

NOTE Confidence: 0.8259487

00:34:15.416 --> 00:34:17.973 do want to emphasize patients 1

NOTE Confidence: 0.8259487

00:34:17.973 --> 00:34:21.257 to 30 years were eligible and we

NOTE Confidence: 0.8259487

00:34:21.257 --> 00:34:23.682 do have patients throughout that

NOTE Confidence: 0.8259487

00:34:23.682 --> 00:34:26.920 range so the majority are under 18.

NOTE Confidence: 0.77742743

00:34:29.620 --> 00:34:33.176 This time is expected to accrue 1400

NOTE Confidence: 0.77742743

00:34:33.176 --> 00:34:36.404 patients over 4.4 years, most powered

NOTE Confidence: 0.77742743

00:34:36.404 --> 00:34:40.580 for a 5% difference in four year EFS.

NOTE Confidence: 0.77742743

00:34:40.580 --> 00:34:43.700 However, it only enrolled 847 patients

NOTE Confidence: 0.77742743

00:34:43.700 --> 00:34:47.383 because went at that point to the

NOTE Confidence: 0.77742743

00:34:47.383 --> 00:34:50.401 results of the precursor study was

NOTE Confidence: 0.77742743

00:34:50.401 --> 00:34:53.108 available in that precursor study.

NOTE Confidence: 0.77742743

00:34:53.110 --> 00:34:56.740 AALL 0434 randomized to know Larabee

NOTE Confidence: 0.77742743

00:34:56.740 --> 00:35:00.408 nor not and was. Found to be.

NOTE Confidence: 0.7045952

00:35:02.800 --> 00:35:06.424 Very much an advantage to having

NOTE Confidence: 0.7045952

00:35:06.424 --> 00:35:10.490 allara been with event free survival.

NOTE Confidence: 0.7045952

00:35:10.490 --> 00:35:13.730 Advantage of about 5% and also

NOTE Confidence: 0.7045952

00:35:13.730 --> 00:35:16.500 at lower CNS recurrence rate.

NOTE Confidence: 0.7045952

00:35:16.500 --> 00:35:20.005 So that's the study was

NOTE Confidence: 0.7045952

00:35:20.005 --> 00:35:23.510 amended and closed early and.

NOTE Confidence: 0.7045952

00:35:23.510 --> 00:35:27.136 This is what was presented is the

NOTE Confidence: 0.7045952

00:35:27.136 --> 00:35:30.581 patients that were enrolled at 800

NOTE Confidence: 0.7045952

00:35:30.581 --> 00:35:34.163 approximately 800 patients and for TI.

NOTE Confidence: 0.7045952

00:35:34.170 --> 00:35:38.658 Don't know why this keeps moving for TLL,

NOTE Confidence: 0.7045952

00:35:38.660 --> 00:35:42.576 the. There was no difference.

NOTE Confidence: 0.7045952

00:35:42.576 --> 00:35:45.869 Arm A was the standard arm in ARM,

NOTE Confidence: 0.7045952

00:35:45.870 --> 00:35:48.378 B was upper to some arm.

NOTE Confidence: 0.7045952

00:35:48.380 --> 00:35:50.780 There was no difference in three

NOTE Confidence: 0.7045952

00:35:50.780 --> 00:35:53.410 year EFS or in three year.

NOTE Confidence: 0.7045952

00:35:53.410 --> 00:35:56.498 Overall survival by arm.

NOTE Confidence: 0.7045952

00:35:56.500 --> 00:36:00.145 But when one looked at it by risk group,

NOTE Confidence: 0.7045952

00:36:00.150 --> 00:36:02.964 those who were standard risk or who

NOTE Confidence: 0.7045952

00:36:02.964 --> 00:36:06.388 had the lowest MRD at the end of

NOTE Confidence: 0.7045952

00:36:06.388 --> 00:36:08.518 consolidation had a clear advantage

NOTE Confidence: 0.7045952

00:36:08.607 --> 00:36:11.520 of 92% versus 85% in three year FS.

NOTE Confidence: 0.7045952

00:36:11.520 --> 00:36:13.956 And there was a similar advantage

NOTE Confidence: 0.7045952

00:36:13.956 --> 00:36:15.580 in their intermediate risk.

NOTE Confidence: 0.7045952

00:36:15.580 --> 00:36:18.415 There was no advantage for purchase map,

NOTE Confidence: 0.7045952

00:36:18.420 --> 00:36:21.849 but in fact those who got burnt to the

NOTE Confidence: 0.7045952

00:36:21.849 --> 00:36:25.326 map did worse for very high risk TLL.

NOTE Confidence: 0.7045952

00:36:25.330 --> 00:36:27.646 Those who had high.

NOTE Confidence: 0.7045952

00:36:27.646 --> 00:36:31.770 End of consolidation burden or who were?

NOTE Confidence: 0.7045952

00:36:31.770 --> 00:36:34.595 Early relapse patients and this

NOTE Confidence: 0.7045952

00:36:34.595 --> 00:36:36.290 was statistically significant

NOTE Confidence: 0.7045952

00:36:36.290 --> 00:36:38.120 for unclear reasons,

NOTE Confidence: 0.7045952

00:36:38.120 --> 00:36:41.956 though it was speculated by the authors

NOTE Confidence: 0.7045952

00:36:41.956 --> 00:36:46.198 that this could relate to early toxicity.

NOTE Confidence: 0.7045952

00:36:46.200 --> 00:36:49.080 So in terms of the

NOTE Confidence: 0.7045952

00:36:49.080 --> 00:36:50.808 lymphoblastic lymphoma outcomes,

NOTE Confidence: 0.7045952

00:36:50.810 --> 00:36:53.106 there was an advantage.

NOTE Confidence: 0.7045952

00:36:53.106 --> 00:36:55.402 A statistically clear advantage

NOTE Confidence: 0.7045952

00:36:55.402 --> 00:36:57.160 of Virtusa ma'am,

NOTE Confidence: 0.7045952

00:36:57.160 --> 00:37:00.295 both for event free survival

NOTE Confidence: 0.7045952

00:37:00.295 --> 00:37:02.176 and overall survival.

NOTE Confidence: 0.7045952

00:37:02.180 --> 00:37:05.390 Up about 7 to 8%.

NOTE Confidence: 0.8308252

00:37:06.390 --> 00:37:08.539 We wanted to compare outcomes on 12th.

NOTE Confidence: 0.8308252

00:37:08.540 --> 00:37:10.920 Oh, that's what I did.

NOTE Confidence: 0.8308252

00:37:10.920 --> 00:37:14.590 OK, so the differences in

NOTE Confidence: 0.8308252

00:37:14.590 --> 00:37:17.526 induction therapy were remarkable

NOTE Confidence: 0.8308252

00:37:17.526 --> 00:37:21.219 in that there was a higher.

NOTE Confidence: 0.8308252

00:37:21.220 --> 00:37:24.046 So actually, going back with this

NOTE Confidence: 0.8308252

00:37:24.046 --> 00:37:27.088 and with this study truncated and

NOTE Confidence: 0.8308252

00:37:27.088 --> 00:37:30.286 with the recent AALLO 434 results,

NOTE Confidence: 0.8308252

00:37:30.290 --> 00:37:33.400 there were some opportunities to

NOTE Confidence: 0.8308252

00:37:33.400 --> 00:37:35.888 compare some strategies because

NOTE Confidence: 0.8308252

00:37:35.888 --> 00:37:39.253 the Miller Bing was not included

NOTE Confidence: 0.8308252

00:37:39.253 --> 00:37:41.903 in this current study because

NOTE Confidence: 0.8308252

00:37:42.001 --> 00:37:45.019 those results were not known and.

NOTE Confidence: 0.8308252

00:37:45.020 --> 00:37:50.870 Therefore, the. The.

NOTE Confidence: 0.8308252

00:37:50.870 --> 00:37:53.606 First thing that was examined was

NOTE Confidence: 0.8308252

00:37:53.606 --> 00:37:56.989 in those who got a little over 3,

NOTE Confidence: 0.8308252

00:37:56.990 --> 00:37:59.170 four, which would be known

NOTE Confidence: 0.8308252

00:37:59.170 --> 00:38:00.914 allara being an induction,

NOTE Confidence: 0.8308252

00:38:00.920 --> 00:38:03.125 but could get in conduct

NOTE Confidence: 0.8308252

00:38:03.125 --> 00:38:05.330 consolidation and then now I'm

NOTE Confidence: 0.8308252

00:38:05.419 --> 00:38:08.342 sorry this is end of induction, MRD.

NOTE Confidence: 0.8308252

00:38:08.342 --> 00:38:10.934 Those who got no LL Bean

NOTE Confidence: 0.8308252

00:38:10.934 --> 00:38:13.159 versus all comers for 1231.

NOTE Confidence: 0.8308252

00:38:13.160 --> 00:38:15.782 There was actually much higher MRD

NOTE Confidence: 0.8308252

00:38:15.782 --> 00:38:18.839 negativity in those in the later study.

NOTE Confidence: 0.8308252

00:38:18.840 --> 00:38:21.798 The 1231 that looked at Partism.

NOTE Confidence: 0.8308252

00:38:21.800 --> 00:38:23.620 Which is interesting because MRD

NOTE Confidence: 0.8308252

00:38:23.620 --> 00:38:25.950 says we typically think of as

NOTE Confidence: 0.8308252

00:38:25.950 --> 00:38:27.726 predictive of long-term outcomes,

NOTE Confidence: 0.8308252

00:38:27.730 --> 00:38:28.458 but not.

NOTE Confidence: 0.8308252

00:38:28.458 --> 00:38:30.642 It's not the only predictor in

NOTE Confidence: 0.8308252

00:38:30.642 --> 00:38:32.860 that kind of emphasizes that.

NOTE Confidence: 0.8308252

00:38:32.860 --> 00:38:35.254 The other thing that was really

NOTE Confidence: 0.8308252

00:38:35.254 --> 00:38:37.606 remarkable was that there was a

NOTE Confidence: 0.8308252

00:38:37.606 --> 00:38:39.664 lot more high grade toxicity in

NOTE Confidence: 0.8308252

00:38:39.664 --> 00:38:41.731 the PARTISM study compared to

NOTE Confidence: 0.8308252

00:38:41.731 --> 00:38:43.916 the previous Miller being study,

NOTE Confidence: 0.8308252

00:38:43.920 --> 00:38:46.349 and this is not clear why it's

NOTE Confidence: 0.8308252

00:38:46.349 --> 00:38:49.204 speculated to be due to the dexamethasone

NOTE Confidence: 0.8308252

00:38:49.204 --> 00:38:51.814 and the extra peg asparagine ease.

NOTE Confidence: 0.8308252

00:38:51.820 --> 00:38:53.152 So while the?

NOTE Confidence: 0.8308252

00:38:53.152 --> 00:38:55.372 Total number of events or

NOTE Confidence: 0.8308252

00:38:55.372 --> 00:38:57.795 toxic events were higher in

NOTE Confidence: 0.8308252

00:38:57.795 --> 00:39:00.200 the precursor study that 0434.

NOTE Confidence: 0.8308252

00:39:00.200 --> 00:39:02.804 There was a much higher rate of

NOTE Confidence: 0.8308252

00:39:02.804 --> 00:39:05.580 higher grade ones and they were

NOTE Confidence: 0.8308252

00:39:05.580 --> 00:39:07.680 due to infections predominantly

NOTE Confidence: 0.8308252

00:39:07.680 --> 00:39:10.170 and particularly fungal infections.

NOTE Confidence: 0.8308252

00:39:10.170 --> 00:39:13.495 The next thing that was examined was

NOTE Confidence: 0.8308252

00:39:13.495 --> 00:39:15.870 the cranial radiation, 'cause again,

NOTE Confidence: 0.8308252

00:39:15.870 --> 00:39:20.182 we had this opportunity to look in 043, four.

NOTE Confidence: 0.8308252

00:39:20.182 --> 00:39:23.254 90% of patients had cranial radiation.

NOTE Confidence: 0.8308252

00:39:23.260 --> 00:39:26.730 While in the current 1231,

NOTE Confidence: 0.8308252

00:39:26.730 --> 00:39:32.266 only 10% did and can see that the.

NOTE Confidence: 0.7734715

00:39:36.290 --> 00:39:41.954 The. CNS relapse rate was

NOTE Confidence: 0.7734715

00:39:41.954 --> 00:39:46.109 higher in the 1231 study.

NOTE Confidence: 0.7734715

00:39:46.110 --> 00:39:47.950 But not overall relapse,

NOTE Confidence: 0.7734715

00:39:47.950 --> 00:39:51.670 and that's what we call Pete sometimes.

NOTE Confidence: 0.7734715

00:39:51.670 --> 00:39:54.520 The Pillsbury Doughboy effect where you

NOTE Confidence: 0.7734715

00:39:54.520 --> 00:39:57.729 shift relapses to bone marrow relapses,

NOTE Confidence: 0.7734715

00:39:57.730 --> 00:40:00.330 but there was no diff.

NOTE Confidence: 0.7734715

00:40:00.330 --> 00:40:01.965 And overall relapses,

NOTE Confidence: 0.7734715

00:40:01.965 --> 00:40:05.780 so this was felt as justification that

NOTE Confidence: 0.7734715

00:40:05.875 --> 00:40:09.420 cranial radiation could be illuminated.

NOTE Confidence: 0.7734715

00:40:09.420 --> 00:40:12.489 So next I'd like to go to an abstract

NOTE Confidence: 0.7734715

00:40:12.489 --> 00:40:15.588 that looks at Linda to mmap versus

NOTE Confidence: 0.7734715

00:40:15.588 --> 00:40:18.110 intensive chemo for first relapse,

NOTE Confidence: 0.7734715

00:40:18.110 --> 00:40:20.216 standard of care in first relapse

NOTE Confidence: 0.7734715

00:40:20.216 --> 00:40:22.740 therapy is to give three blocks

NOTE Confidence: 0.7734715

00:40:22.740 --> 00:40:24.318 of intensive chemotherapy.

NOTE Confidence: 0.7734715

00:40:24.320 --> 00:40:27.232 This is from a European study and

NOTE Confidence: 0.7734715

00:40:27.232 --> 00:40:30.143 they call those blocks HC 1 HC 2

NOTE Confidence: 0.7734715

00:40:30.143 --> 00:40:32.792 and HD three in this study after

NOTE Confidence: 0.7734715

00:40:32.792 --> 00:40:35.750 the first 2 blocks patients were

NOTE Confidence: 0.7734715

00:40:35.750 --> 00:40:39.290 randomized to blend into mmap or two.

NOTE Confidence: 0.7734715

00:40:39.290 --> 00:40:41.992 Third block and then they went to

NOTE Confidence: 0.7734715

00:40:41.992 --> 00:40:44.230 stem cell transplant if they could.

NOTE Confidence: 0.7734715

00:40:44.230 --> 00:40:46.660 And this study also ended early.

NOTE Confidence: 0.7734715

00:40:46.660 --> 00:40:48.982 It was supposed to enroll 202

NOTE Confidence: 0.7734715

00:40:48.982 --> 00:40:51.429 patients and only 100 patients or

NOTE Confidence: 0.7734715

00:40:51.429 --> 00:40:53.889 so were enrolled because there was

NOTE Confidence: 0.7734715

00:40:53.889 --> 00:40:56.795 a clear result that there was an

NOTE Confidence: 0.7734715

00:40:56.795 --> 00:41:00.820 advantage of blended to mmap both in.

NOTE Confidence: 0.7734715

00:41:00.820 --> 00:41:01.672 Add.

NOTE Confidence: 0.7734715

00:41:01.672 --> 00:41:06.784 Event free survival and in time

NOTE Confidence: 0.7734715

00:41:06.784 --> 00:41:10.760 from diagnosis to relapse.

NOTE Confidence: 0.7734715

00:41:10.760 --> 00:41:12.780 There is also an advantage.

NOTE Confidence: 0.7734715

00:41:12.780 --> 00:41:14.885 A significant advantage in overall

NOTE Confidence: 0.7734715

00:41:14.885 --> 00:41:17.610 survival in the blue netuma Bab arm.

NOTE Confidence: 0.79039747

00:41:20.030 --> 00:41:23.060 There was superior MRD remission that

NOTE Confidence: 0.79039747

00:41:23.060 --> 00:41:26.365 was assessed by PCR in the billing

NOTE Confidence: 0.79039747

00:41:26.365 --> 00:41:29.701 to mmap arm overall and it was more

NOTE Confidence: 0.79039747

00:41:29.701 --> 00:41:32.865 remarkable or in those that had a

NOTE Confidence: 0.79039747

00:41:32.865 --> 00:41:35.495 higher tumor burden load initially,

NOTE Confidence: 0.79039747

00:41:35.495 --> 00:41:39.520 so it was most remarkable in those

NOTE Confidence: 0.79039747

00:41:39.630 --> 00:41:42.558 who had more MRD at baseline.

NOTE Confidence: 0.79039747

00:41:42.560 --> 00:41:45.435 There was very notably much

NOTE Confidence: 0.79039747

00:41:45.435 --> 00:41:46.585 decreased toxicity,

NOTE Confidence: 0.79039747

00:41:46.590 --> 00:41:50.040 so while overall toxicity was similar,

NOTE Confidence: 0.79039747

00:41:50.040 --> 00:41:54.135 there was a much lower rate of

NOTE Confidence: 0.79039747

00:41:54.135 --> 00:41:57.510 serious toxicity of 24% versus 43%,

NOTE Confidence: 0.79039747

00:41:57.510 --> 00:42:01.535 and those are greater than Grade 3,

NOTE Confidence: 0.79039747

00:42:01.540 --> 00:42:04.399 so this changes.

NOTE Confidence: 0.79039747

65

00:42:04.400 --> 00:42:05.706 The construct,

NOTE Confidence: 0.79039747

00:42:05.706 --> 00:42:08.318 because previously the standard,

NOTE Confidence: 0.79039747

00:42:08.320 --> 00:42:14.186 was to get three blocks of chemotherapy.

NOTE Confidence: 0.79039747

00:42:14.190 --> 00:42:15.930 Before transplant in first relapse

NOTE Confidence: 0.79039747

00:42:15.930 --> 00:42:18.063 and this also mirrors a similar

NOTE Confidence: 0.79039747

00:42:18.063 --> 00:42:20.331 see OG study that also found some

NOTE Confidence: 0.79039747

00:42:20.331 --> 00:42:22.487 results that were reported last year.

NOTE Confidence: 0.78015244

00:42:26.870 --> 00:42:29.372 What there is always concerned about

NOTE Confidence: 0.78015244

00:42:29.372 --> 00:42:31.040 neurological toxicity with cytokine

NOTE Confidence: 0.78015244

00:42:31.100 --> 00:42:32.780 release syndrome with netuma.

NOTE Confidence: 0.78015244

00:42:32.780 --> 00:42:34.464 But while there were

NOTE Confidence: 0.78015244

00:42:34.464 --> 00:42:35.727 more neurological events,

NOTE Confidence: 0.78015244

00:42:35.730 --> 00:42:38.530 there were no Grade 3 or higher

NOTE Confidence: 0.78015244

00:42:38.530 --> 00:42:41.638 events in CR S and there weren't.

NOTE Confidence: 0.78015244

00:42:41.640 --> 00:42:44.752 There was really not an increase in severe

NOTE Confidence: 0.78015244

00:42:44.752 --> 00:42:47.549 events or moderate or severe events,

NOTE Confidence: 0.78015244

00:42:47.550 --> 00:42:50.742 so the third study that also relates

NOTE Confidence: 0.78015244

00:42:50.742 --> 00:42:54.162 to blend into my map has to do

NOTE Confidence: 0.78015244

00:42:54.162 --> 00:42:56.580 with whether Blend into my map.

NOTE Confidence: 0.78015244

00:42:56.580 --> 00:43:01.690 Treatment prior to car affects car outcomes.

NOTE Confidence: 0.78015244

00:43:01.690 --> 00:43:04.630 And this is a multi site study.

NOTE Confidence: 0.78015244

00:43:04.630 --> 00:43:07.150 I'm so just there will be

NOTE Confidence: 0.78015244

00:43:07.150 --> 00:43:08.830 a separate car session,

NOTE Confidence: 0.78015244

00:43:08.830 --> 00:43:11.693 but this slide is here if people

NOTE Confidence: 0.78015244

00:43:11.693 --> 00:43:14.288 want to look at this later.

NOTE Confidence: 0.78015244

00:43:14.290 --> 00:43:17.332 But basically a patients T cells

NOTE Confidence: 0.78015244

00:43:17.332 --> 00:43:19.926 are harvested and then they

NOTE Confidence: 0.78015244

00:43:19.926 --> 00:43:22.770 are expanded and then they are.

NOTE Confidence: 0.78015244

00:43:22.770 --> 00:43:28.446 They. Are transfected to T cells

NOTE Confidence: 0.78015244

00:43:28.446 --> 00:43:32.230 via viral vector 2.

NOTE Confidence: 0.78015244

00:43:32.230 --> 00:43:36.365 Have T cell receptor gamma and

NOTE Confidence: 0.78015244

00:43:36.365 --> 00:43:38.033 then often something else.

NOTE Confidence: 0.78015244

00:43:38.040 --> 00:43:41.384 In this case it was for one BB,

NOTE Confidence: 0.78015244

00:43:41.390 --> 00:43:45.184 but it can be different things and

NOTE Confidence: 0.78015244

00:43:45.184 --> 00:43:48.140 it's reinfused and then it can.

NOTE Confidence: 0.78015244

00:43:48.140 --> 00:43:51.035 Go after the particular marker

NOTE Confidence: 0.78015244

00:43:51.035 --> 00:43:53.930 on the on the tumor.

NOTE Confidence: 0.78015244

00:43:53.930 --> 00:43:56.744 So sitting 19 modulation represents a

NOTE Confidence: 0.78015244

00:43:56.744 --> 00:43:59.870 mechanism of resistance to CD 19 targeting.

NOTE Confidence: 0.78015244

00:43:59.870 --> 00:44:03.142 It's both blue 2:00 AM AB and CD19

NOTE Confidence: 0.78015244

00:44:03.142 --> 00:44:07.130 car T cells are associated lineages.

NOTE Confidence: 0.78015244

00:44:07.130 --> 00:44:08.396 Switch CD 19.

NOTE Confidence: 0.78015244

00:44:08.396 --> 00:44:09.240 Lawson CD.

NOTE Confidence: 0.78015244

00:44:09.240 --> 00:44:11.340 19 antigen downregulation becoming dim,

NOTE Confidence: 0.78015244

00:44:11.340 --> 00:44:13.818 and there's just limited impact on

NOTE Confidence: 0.78015244

00:44:13.818 --> 00:44:16.390 the how they impact each other.

NOTE Confidence: 0.78015244

00:44:16.390 --> 00:44:18.500 This was a multicenter study.

NOTE Confidence: 0.78015244

00:44:18.500 --> 00:44:20.605 There were three different car

NOTE Confidence: 0.78015244

00:44:20.605 --> 00:44:21.868 T cell constructs,

NOTE Confidence: 0.78015244

00:44:21.870 --> 00:44:24.810 and it was a seven site study.

NOTE Confidence: 0.78015244

00:44:24.810 --> 00:44:27.540 Their median post infusion followed was

NOTE Confidence: 0.78015244

00:44:27.540 --> 00:44:31.480 2.3 years and this occurred over seven years.

NOTE Confidence: 0.78015244

00:44:31.480 --> 00:44:32.008 Um,

NOTE Confidence: 0.78015244

00:44:32.008 --> 00:44:35.704 75 of the 420 patients had had

NOTE Confidence: 0.78015244

00:44:35.704 --> 00:44:36.760 previous blenner,

NOTE Confidence: 0.78015244

00:44:36.760 --> 00:44:40.084 of which 57.3% achieved CR and

NOTE Confidence: 0.78015244

00:44:40.084 --> 00:44:43.609 the median time from last minute

NOTE Confidence: 0.78015244

00:44:43.609 --> 00:44:47.197 to the current Fusion in these

NOTE Confidence: 0.78015244

00:44:47.197 --> 00:44:49.480 patients was 129 days.

NOTE Confidence: 0.78015244

00:44:49.480 --> 00:44:52.350 So there was no difference in those

NOTE Confidence: 0.78015244

00:44:52.350 --> 00:44:55.378 who had had Blender and prior blenna

NOTE Confidence: 0.78015244

00:44:55.378 --> 00:44:59.778 and those who did not in terms of MRD status,

NOTE Confidence: 0.78015244

00:44:59.780 --> 00:45:03.212 whether they had an empty or M3 marrow

NOTE Confidence: 0.78015244

00:45:03.212 --> 00:45:04.926 CNS status, extramedullary disease,

NOTE Confidence: 0.78015244

00:45:04.926 --> 00:45:06.210 or circulating glass.

NOTE Confidence: 0.78015244

00:45:06.210 --> 00:45:09.846 There was a higher rate in those who had

NOTE Confidence: 0.78015244

00:45:09.846 --> 00:45:13.495 prior brunette with the KM T2A R mutation,

NOTE Confidence: 0.78015244

00:45:13.500 --> 00:45:17.070 maybe indicating that there were more younger

NOTE Confidence: 0.78015244

00:45:17.070 --> 00:45:20.457 patients 'cause that occurs more in infants.

NOTE Confidence: 0.78015244

00:45:20.460 --> 00:45:24.093 And and the overall response to the

NOTE Confidence: 0.78015244

00:45:24.093 --> 00:45:28.098 car was great in these 120 patients,

NOTE Confidence: 0.78015244

00:45:28.100 --> 00:45:29.741 91% achieved CR,

NOTE Confidence: 0.78015244

00:45:29.741 --> 00:45:33.023 88% were MRD negative and the

NOTE Confidence: 0.78015244

00:45:33.023 --> 00:45:35.200 relapse rate was 39.8%,

NOTE Confidence: 0.78015244

00:45:35.200 --> 00:45:35.696 however.

NOTE Confidence: 0.78015244

00:45:35.696 --> 00:45:38.176 Blender patients are the ones

NOTE Confidence: 0.78015244

00:45:38.176 --> 00:45:41.206 who had previously know were more

NOTE Confidence: 0.78015244

00:45:41.206 --> 00:45:43.606 likely to have residual disease.

NOTE Confidence: 0.78015244

00:45:43.610 --> 00:45:45.378 Post CD 19 car,

NOTE Confidence: 0.78015244

00:45:45.378 --> 00:45:49.365 so it was 18% if one had prior blina

NOTE Confidence: 0.78015244

00:45:49.365 --> 00:45:52.910 and only 7% if there was previous blender.

NOTE Confidence: 0.78015244

00:45:52.910 --> 00:45:55.574 This also corresponded to worse relapse

NOTE Confidence: 0.78015244

00:45:55.574 --> 00:45:58.230 free survival both at six months.

NOTE Confidence: 0.78015244

00:45:58.230 --> 00:46:01.324 Anna, 12 months and the median relapse.

NOTE Confidence: 0.78015244

00:46:01.330 --> 00:46:03.540 Free survival was twenty months.

NOTE Confidence: 0.78015244

00:46:03.540 --> 00:46:07.236 If one had had previous planner and 45

NOTE Confidence: 0.78015244

00:46:07.236 --> 00:46:08.930 months. If there had been no blender.

NOTE Confidence: 0.8373493

00:46:11.940 --> 00:46:13.760 So we're not is associated.

NOTE Confidence: 0.8373493

00:46:13.760 --> 00:46:16.259 Also was also associated with a higher

NOTE Confidence: 0.8373493

00:46:16.259 --> 00:46:18.859 incidence of CD 19 modulation pre car.

NOTE Confidence: 0.8373493

00:46:18.860 --> 00:46:21.038 So the incidents of CD 19,

NOTE Confidence: 0.8373493

00:46:21.040 --> 00:46:22.768 negative, dim or partial

NOTE Confidence: 0.8373493

00:46:22.768 --> 00:46:25.360 expression prior to the car was.

NOTE Confidence: 0.8373493

00:46:25.360 --> 00:46:28.006 Was higher in prior blender patients,

NOTE Confidence: 0.8373493

00:46:28.010 --> 00:46:31.626 13% versus 6% and in patients in which

NOTE Confidence: 0.8373493

00:46:31.626 --> 00:46:35.550 there was a pre and post Lena CD 19

NOTE Confidence: 0.8373493

00:46:35.550 --> 00:46:38.150 expression 11% had evolution to CD.

NOTE Confidence: 0.8373493

00:46:38.150 --> 00:46:39.470 19 dim expression.

NOTE Confidence: 0.84853727

00:46:42.460 --> 00:46:45.484 Going to change gears now and talk a

NOTE Confidence: 0.84853727

00:46:45.484 --> 00:46:47.822 little bit about toxicities because

NOTE Confidence: 0.84853727

00:46:47.822 --> 00:46:50.816 and listen to young adults were

NOTE Confidence: 0.84853727

00:46:50.816 --> 00:46:53.330 found to have inferior outcomes

NOTE Confidence: 0.84853727

00:46:53.330 --> 00:46:56.228 compared to children and do better

NOTE Confidence: 0.84853727

00:46:56.230 --> 00:47:00.416 when they are treated with PD type.

NOTE Confidence: 0.84853727

00:47:00.420 --> 00:47:04.004 Regiments we can talk about this a little

NOTE Confidence: 0.84853727

00:47:04.004 --> 00:47:07.140 bit more, but there's some trade offs.

NOTE Confidence: 0.84853727

00:47:07.140 --> 00:47:10.716 And so as especially in the early 20s,

NOTE Confidence: 0.84853727

00:47:10.720 --> 00:47:13.624 there is an advantage with pediatric

NOTE Confidence: 0.84853727

00:47:13.624 --> 00:47:16.099 regiments rather than this C vad,

NOTE Confidence: 0.84853727

00:47:16.100 --> 00:47:19.364 this has to be reassessed in

NOTE Confidence: 0.84853727

00:47:19.364 --> 00:47:22.570 the era of cellular therapy.

NOTE Confidence: 0.84853727

00:47:22.570 --> 00:47:25.639 So the goal of this study was to look

NOTE Confidence: 0.84853727

00:47:25.639 --> 00:47:28.474 at bone toxicities and it was found

NOTE Confidence: 0.84853727

00:47:28.474 --> 00:47:31.272 that this is a retrospective study

NOTE Confidence: 0.84853727

00:47:31.272 --> 00:47:34.042 of Dana Farber consortia patients

NOTE Confidence: 0.84853727

00:47:34.042 --> 00:47:37.750 who were up to 50 years and initially

NOTE Confidence: 0.84853727

00:47:37.750 --> 00:47:40.715 they were true with the coli based

NOTE Confidence: 0.84853727

00:47:40.715 --> 00:47:43.634 ones and had 30 weeks of asparagine

NOTE Confidence: 0.84853727

00:47:43.634 --> 00:47:46.219 ace depletion and then later,

NOTE Confidence: 0.84853727

00:47:46.220 --> 00:47:48.276 this changed to PEG.

NOTE Confidence: 0.84853727

00:47:48.276 --> 00:47:50.846 And steroid Dennis Progenies associates

NOTE Confidence: 0.84853727

00:47:50.846 --> 00:47:53.517 Austin across is glucose corduroy,

NOTE Confidence: 0.84853727

00:47:53.520 --> 00:47:53.985 corticoids,

NOTE Confidence: 0.84853727

00:47:53.985 --> 00:47:56.310 disrupt osteoblasts and cause ischaemia.

NOTE Confidence: 0.84853727

00:47:56.310 --> 00:47:59.124 It's not really clear how asparagine

NOTE Confidence: 0.84853727

00:47:59.124 --> 00:48:01.889 ease results in Aston across is,

NOTE Confidence: 0.84853727

00:48:01.890 --> 00:48:04.220 but it is highly associated,

NOTE Confidence: 0.84853727

00:48:04.220 --> 00:48:06.740 maybe due to hypercoagulability in

NOTE Confidence: 0.84853727

00:48:06.740 --> 00:48:09.260 altered lipid metabolism and previous

NOTE Confidence: 0.84853727

00:48:09.336 --> 00:48:11.808 ranges and kids was incidents of

NOTE Confidence: 0.84853727

00:48:11.808 --> 00:48:14.574 osteonecrosis of 69% much higher in

NOTE Confidence: 0.84853727

00:48:14.574 --> 00:48:18.919 adolescence as high in the high teens or 20s.

NOTE Confidence: 0.84853727

00:48:18.920 --> 00:48:22.441 And a good proportion needs surgery and

NOTE Confidence: 0.84853727

00:48:22.441 --> 00:48:25.598 and joint replacement as as 20 year olds.

NOTE Confidence: 0.84853727

00:48:25.600 --> 00:48:28.096 So the goal is to understand

NOTE Confidence: 0.84853727

00:48:28.096 --> 00:48:30.490 this incidence and risk factors.

NOTE Confidence: 0.84853727

00:48:30.490 --> 00:48:33.652 This has this study had 367

NOTE Confidence: 0.84853727

00:48:33.652 --> 00:48:35.760 patients from 25 institutions.

NOTE Confidence: 0.84853727

00:48:35.760 --> 00:48:39.876 And it was found that 17% of them

NOTE Confidence: 0.84853727

00:48:39.876 --> 00:48:42.068 developed osteonecrosis and a

NOTE Confidence: 0.84853727

00:48:42.068 --> 00:48:45.544 median time to event was 1.6 years

NOTE Confidence: 0.84853727

00:48:45.544 --> 00:48:48.764 and 12% developed a fracture with

NOTE Confidence: 0.84853727

00:48:48.764 --> 00:48:53.200 median time to event of 1.4 years.

NOTE Confidence: 0.84853727

00:48:53.200 --> 00:48:55.576 When one looked at risk factors,

NOTE Confidence: 0.84853727

00:48:55.580 --> 00:48:58.789 those under 30 years had a 21% risk,

NOTE Confidence: 0.84853727

00:48:58.789 --> 00:49:01.792 so this is really a condition of

NOTE Confidence: 0.84853727

00:49:01.792 --> 00:49:03.770 adolescents and young adults.

NOTE Confidence: 0.84853727

00:49:03.770 --> 00:49:06.618 With only 8% in those over 30 years

NOTE Confidence: 0.84853727

00:49:06.618 --> 00:49:09.115 and there was a much higher risk

NOTE Confidence: 0.84853727

00:49:09.115 --> 00:49:12.009 in those who had peg based therapy.

NOTE Confidence: 0.84853727

00:49:12.010 --> 00:49:13.258 Rather than E.

NOTE Confidence: 0.84853727

00:49:13.258 --> 00:49:14.506 Coli based therapy,

NOTE Confidence: 0.84853727

00:49:14.510 --> 00:49:18.110 almost a fivefold increased risk.

NOTE Confidence: 0.84853727

00:49:18.110 --> 00:49:20.565 So the potential mechanisms are

NOTE Confidence: 0.84853727

00:49:20.565 --> 00:49:23.570 not known in the later eras,

NOTE Confidence: 0.84853727

00:49:23.570 --> 00:49:25.550 along with Pegasus Virginis

NOTE Confidence: 0.84853727

00:49:25.550 --> 00:49:26.540 more dexamethasone.

NOTE Confidence: 0.84853727

00:49:26.540 --> 00:49:28.845 Dexamethasone is uniformly used and

NOTE Confidence: 0.84853727

00:49:28.845 --> 00:49:31.150 it was proposed that asparagine

NOTE Confidence: 0.84853727

00:49:31.219 --> 00:49:33.487 ease could cause hypoalbuminemia,

NOTE Confidence: 0.84853727

00:49:33.490 --> 00:49:35.786 which decreases dex clearance,

NOTE Confidence: 0.84853727

00:49:35.786 --> 00:49:39.230 and dexamethasone is a steroid more

NOTE Confidence: 0.84853727

00:49:39.325 --> 00:49:42.457 than Prednisone that is a much

NOTE Confidence: 0.84853727

00:49:42.457 --> 00:49:44.545 higher risk of osteonecrosis.

NOTE Confidence: 0.84853727

00:49:44.550 --> 00:49:46.325 And Asperges clearance is higher

NOTE Confidence: 0.84853727

00:49:46.325 --> 00:49:48.448 free collide that Nino Peg Lated

NOTE Confidence: 0.84853727

00:49:48.448 --> 00:49:50.450 is meant to be there along time,

NOTE Confidence: 0.84853727

00:49:50.450 --> 00:49:51.630 and maybe that's it.

NOTE Confidence: 0.84853727

00:49:51.630 --> 00:49:53.400 The investigators plan to look at

NOTE Confidence: 0.84853727

00:49:53.457 --> 00:49:56.026 asparagine ace levels more closely, and this.

NOTE Confidence: 0.84853727

00:49:56.026 --> 00:49:57.338 I'll just summarize this.

NOTE Confidence: 0.84853727

00:49:57.340 --> 00:50:00.382 This abstract would seem to be made for this.

NOTE Confidence: 0.84853727

00:50:00.390 --> 00:50:03.974 In which this group looked at asperges

NOTE Confidence: 0.84853727

00:50:03.974 --> 00:50:06.869 levels and toxicity and found that

NOTE Confidence: 0.84853727

00:50:06.869 --> 00:50:09.830 high levels of this urge nice was

NOTE Confidence: 0.84853727

00:50:09.927 --> 00:50:12.177 not associated with an increased

NOTE Confidence: 0.84853727

00:50:12.177 --> 00:50:15.366 risk of any of the known toxicities,

NOTE Confidence: 0.84853727

00:50:15.366 --> 00:50:16.770 including pancreatitis, thromboembolism,

NOTE Confidence: 0.84853727

00:50:16.770 --> 00:50:18.800 or osteonecrosis.

NOTE Confidence: 0.84853727

00:50:18.800 --> 00:50:22.238 So the the answer it may be not as

NOTE Confidence: 0.84853727

00:50:22.238 --> 00:50:25.199 simple as that and may have to be

NOTE Confidence: 0.84853727

00:50:25.199 --> 00:50:28.229 looked at a little more closely.

NOTE Confidence: 0.84853727

00:50:28.230 --> 00:50:30.744 We have several studies open here

NOTE Confidence: 0.84853727

00:50:30.744 --> 00:50:32.420 at Yale that build

NOTE Confidence: 0.8508311

00:50:32.505 --> 00:50:36.530 on this. We have a study of.

NOTE Confidence: 0.8508311

00:50:36.530 --> 00:50:39.446 Tessa Jean Luc's Loosle Carty 19.

NOTE Confidence: 0.8508311

00:50:39.450 --> 00:50:42.360 Made by Novartis in first line,

NOTE Confidence: 0.8508311

00:50:42.360 --> 00:50:45.209 high risk patients who are MRD positive

NOTE Confidence: 0.8508311

00:50:45.209 --> 00:50:48.147 and end up consolidation that goes up

NOTE Confidence: 0.8508311

00:50:48.147 --> 00:50:51.398 to 25 years of age were investigating

NOTE Confidence: 0.8508311

00:50:51.398 --> 00:50:54.998 blinatumomab in standard risk patients,

NOTE Confidence: 0.8508311

00:50:55.000 --> 00:50:58.465 again with a similar goal of trying

NOTE Confidence: 0.8508311

00:50:58.465 --> 00:51:00.520 to limit chemotherapy eventually

NOTE Confidence: 0.8508311

00:51:00.520 --> 00:51:03.388 and then we're staying ina choose

NOTE Confidence: 0.8508311

00:51:03.388 --> 00:51:06.907 the map in high risk PML patients.

NOTE Confidence: 0.8508311

00:51:06.910 --> 00:51:09.898 To 25 years and we have a study of

NOTE Confidence: 0.8508311

00:51:09.898 --> 00:51:12.272 Pseudomonas derived asparagine ease for

NOTE Confidence: 0.8508311

00:51:12.272 --> 00:51:15.440 those who had hypersensitive reaction to E.

NOTE Confidence: 0.8508311

00:51:15.440 --> 00:51:17.060 Coli drive, despair genese.

NOTE Confidence: 0.8508311

00:51:17.060 --> 00:51:18.275 That's any age.

NOTE Confidence: 0.8508311

00:51:18.280 --> 00:51:22.016 And finally, we have a study where bout

NOTE Confidence: 0.8508311

00:51:22.016 --> 00:51:25.839 to open a blender to mmap with Nivo.

NOTE Confidence: 0.8508311

00:51:25.840 --> 00:51:28.010 And first relapse for patients

NOTE Confidence: 0.8508311

00:51:28.010 --> 00:51:29.746 up to 31 years.

NOTE Confidence: 0.8508311

00:51:29.750 --> 00:51:30.620 So with that,

NOTE Confidence: 0.8508311

00:51:30.620 --> 00:51:33.132 I think you and I hand the floor

NOTE Confidence: 0.8508311

00:51:33.132 --> 00:51:35.556 over to moderate are Doctor Shaw.

NOTE Confidence: 0.7141595

00:51:36.950 --> 00:51:40.766 Thank you very much Doctor Nikolai and talk

NOTE Confidence: 0.7141595

00:51:40.766 --> 00:51:44.997 to Nina for summarizing on the newer data,

NOTE Confidence: 0.7141595

00:51:45.000 --> 00:51:49.795 which were presented at ASH last year.

NOTE Confidence: 0.7141595

00:51:49.800 --> 00:51:52.296 Regarding both pediatric, any Delta LL.

NOTE Confidence: 0.7141595

00:51:52.300 --> 00:51:55.205 So now session is open for questions

NOTE Confidence: 0.7141595

00:51:55.205 --> 00:51:58.950 and when we are waiting for so I think

NOTE Confidence: 0.8004364

00:51:58.950 --> 00:52:02.278 there are some questions there in the chat.

NOTE Confidence: 0.8004364

00:52:02.280 --> 00:52:05.260 Yeah I saw that.

NOTE Confidence: 0.8004364

00:52:05.260 --> 00:52:08.554 Some of them are just comments, but you know.

NOTE Confidence: 0.8004364

00:52:08.554 --> 00:52:11.470 So one of them is addressed to me.

NOTE Confidence: 0.8004364

00:52:11.470 --> 00:52:14.186 Yeah, would you use Hyper C Vad

NOTE Confidence: 0.8004364

00:52:14.186 --> 00:52:16.250 plus blinatumomab approach in your

NOTE Confidence: 0.8004364

00:52:16.250 --> 00:52:18.310 practice today to avoid transplant?

NOTE Confidence: 0.8004364

00:52:18.310 --> 00:52:21.390 So I do have to mention that in that study

NOTE Confidence: 0.8004364

00:52:21.468 --> 00:52:24.478 which I think enrolled about 39 patients,

NOTE Confidence: 0.8004364

00:52:24.480 --> 00:52:27.016 12 patients went to transplant and you know

NOTE Confidence: 0.8004364

00:52:27.016 --> 00:52:29.929 10 of them actually went before relapse.

NOTE Confidence: 0.8004364

00:52:29.930 --> 00:52:31.904 So even folks in MD Anderson

NOTE Confidence: 0.8004364

00:52:31.904 --> 00:52:33.920 who are using this approach,

NOTE Confidence: 0.8004364

00:52:33.920 --> 00:52:36.174 they still using transplant as a modality

NOTE Confidence: 0.8004364

00:52:36.174 --> 00:52:38.406 for this patient after they accomplished

NOTE Confidence: 0.8004364

00:52:38.406 --> 00:52:40.812 CR with without minimal residual disease.

NOTE Confidence: 0.8004364

00:52:40.820 --> 00:52:43.588 So I think the transplant is reserved for

NOTE Confidence: 0.8004364

00:52:43.588 --> 00:52:46.288 high risk patients as defined by their

NOTE Confidence: 0.8004364

00:52:46.288 --> 00:52:48.770 karyotype of maletis pH like status.

NOTE Confidence: 0.8004364

00:52:48.770 --> 00:52:49.775 Anti P53 expression.

NOTE Confidence: 0.8004364

00:52:49.775 --> 00:52:53.239 I have TP 53 mutations so I don't think it.

NOTE Confidence: 0.8004364

00:52:53.240 --> 00:52:55.247 I think it is too soon to say that

NOTE Confidence: 0.8004364

00:52:55.247 --> 00:52:57.230 this particular approach will eliminate

NOTE Confidence: 0.8004364

00:52:57.230 --> 00:52:59.350 the transplant but certainly gives

NOTE Confidence: 0.8004364

00:52:59.350 --> 00:53:01.716 hope to patients who cannot have

NOTE Confidence: 0.8004364

00:53:01.716 --> 00:53:03.220 transplant for whatever reason.

NOTE Confidence: 0.8004364

00:53:03.220 --> 00:53:05.484 An at least maybe a choice for some

NOTE Confidence: 0.8004364

00:53:05.484 --> 00:53:07.766 of those patients who have disease

NOTE Confidence: 0.8004364

00:53:07.766 --> 00:53:09.410 with less risky features.

NOTE Confidence: 0.8807261

00:53:10.420 --> 00:53:13.970 So I and I would say that that is a

NOTE Confidence: 0.8807261

00:53:14.078 --> 00:53:18.038 point of convergence in our literature.

NOTE Confidence: 0.8807261

00:53:18.040 --> 00:53:20.890 So a patient in their 20s,

NOTE Confidence: 0.8807261

00:53:20.890 --> 00:53:24.222 if they came in through a pediatric

NOTE Confidence: 0.8807261

00:53:24.222 --> 00:53:27.211 treatment center, would not accept

NOTE Confidence: 0.8807261

00:53:27.211 --> 00:53:29.919 for certain molecular findings.

NOTE Confidence: 0.8807261

00:53:29.920 --> 00:53:32.060 Would not automatically get transplanted

NOTE Confidence: 0.8807261

00:53:32.060 --> 00:53:34.440 first remission because we have it.

NOTE Confidence: 0.8807261

00:53:34.440 --> 00:53:37.317 We don't use the high perceived backbone,

NOTE Confidence: 0.8807261

00:53:37.320 --> 00:53:40.920 we use the BFM backbone.

NOTE Confidence: 0.8807261

00:53:40.920 --> 00:53:43.452 And use a lot more asparagine

NOTE Confidence: 0.8807261

00:53:43.452 --> 00:53:44.718 ease and methotrexate.

NOTE Confidence: 0.8807261

00:53:44.720 --> 00:53:46.830 But the and and antimetabolites,

NOTE Confidence: 0.8807261

00:53:46.830 --> 00:53:51.006 but the we have we have survival event free

NOTE Confidence: 0.8807261

00:53:51.006 --> 00:53:54.419 survival in the in the 80s in that group,

NOTE Confidence: 0.8807261

00:53:54.420 --> 00:53:55.964 but what I think.

NOTE Confidence: 0.8807261

00:53:55.964 --> 00:53:58.760 But I think the challenges and what

NOTE Confidence: 0.8807261

00:53:58.760 --> 00:54:01.912 we're learning more and This is why I

NOTE Confidence: 0.8807261

00:54:01.912 --> 00:54:04.968 wanted to highlight the toxicity issue.

NOTE Confidence: 0.8807261

00:54:04.970 --> 00:54:07.847 I think what we want to learn

NOTE Confidence: 0.8807261

00:54:07.847 --> 00:54:10.949 more is that it does seem like.

NOTE Confidence: 0.8807261

00:54:10.950 --> 00:54:13.505 Even in patients in their 20s who

NOTE Confidence: 0.8807261

00:54:13.510 --> 00:54:15.705 we call the older patients rather,

NOTE Confidence: 0.8807261

00:54:15.705 --> 00:54:17.895 they have higher rates of infection.

NOTE Confidence: 0.8807261

00:54:17.900 --> 00:54:20.096 They have higher rates of AVN.

NOTE Confidence: 0.8807261

00:54:20.100 --> 00:54:21.930 They have had higher rates

NOTE Confidence: 0.8807261

00:54:21.930 --> 00:54:23.028 of pancreatitis and,

NOTE Confidence: 0.8807261

00:54:23.030 --> 00:54:25.226 and it's not clear how to

NOTE Confidence: 0.8807261

00:54:25.226 --> 00:54:26.690 balance those two things,

NOTE Confidence: 0.8807261

00:54:26.690 --> 00:54:28.772 but they would be treated very

NOTE Confidence: 0.8807261

00:54:28.772 --> 00:54:30.618 differently and they would have

NOTE Confidence: 0.8807261

00:54:30.618 --> 00:54:32.178 good disease free outcomes.

NOTE Confidence: 0.7732424

00:54:33.590 --> 00:54:35.500 So we just want comment.

NOTE Confidence: 0.7732424

00:54:35.500 --> 00:54:37.420 We do use pediatric protocols.

NOTE Confidence: 0.7732424

00:54:37.420 --> 00:54:38.928 Pediatric like protocols become

NOTE Confidence: 0.7732424

00:54:38.928 --> 00:54:40.436 backbone protocols and we're

NOTE Confidence: 0.7732424

00:54:40.436 --> 00:54:42.397 participating in Lion study which

NOTE Confidence: 0.7732424

00:54:42.397 --> 00:54:43.549 uses inotuzumab randomization.

NOTE Confidence: 0.7732424

00:54:43.550 --> 00:54:46.224 So phase three study after initial induction,

NOTE Confidence: 0.7732424

00:54:46.230 --> 00:54:48.150 randomizing patients to two cycles in

NOTE Confidence: 0.7732424

00:54:48.150 --> 00:54:50.819 a tourism up or regular consolidation.

NOTE Confidence: 0.7732424

00:54:50.820 --> 00:54:53.118 This is between H20 and 39,

NOTE Confidence: 0.7732424

00:54:53.120 --> 00:54:56.040 so you know how I perceive what is

NOTE Confidence: 0.7732424

00:54:56.040 --> 00:54:58.024 usually something you would consider

NOTE Confidence: 0.7732424

00:54:58.024 --> 00:55:00.775 for patients who are older than that.

NOTE Confidence: 0.7732424

00:55:00.780 --> 00:55:03.797 And we tried to use again DFM.

NOTE Confidence: 0.7732424

00:55:03.800 --> 00:55:05.252 Backbone augmented BFM backbone

NOTE Confidence: 0.7732424

00:55:05.252 --> 00:55:06.704 protocols for younger patients,

NOTE Confidence: 0.7732424

00:55:06.710 --> 00:55:09.614 so there is a question in the chat.

NOTE Confidence: 0.7732424

00:55:09.620 --> 00:55:11.612 I think both Amarillo Heath and

NOTE Confidence: 0.7732424

00:55:11.612 --> 00:55:14.447 the doctors 8 and that was it was

NOTE Confidence: 0.7732424

00:55:14.447 --> 00:55:16.242 our introduction which reduced us

NOTE Confidence: 0.7732424

00:55:16.242 --> 00:55:19.376 and Doctor Gowda who is one of our

NOTE Confidence: 0.7732424

00:55:19.376 --> 00:55:22.320 adult transplanters asking about.

NOTE Confidence: 0.7732424

00:55:22.320 --> 00:55:24.190 Blender two map consolidation instead

NOTE Confidence: 0.7732424

00:55:24.190 --> 00:55:26.455 of usage of tag asparaginase which

NOTE Confidence: 0.7732424

00:55:26.455 --> 00:55:28.125 is certainly much more difficult

NOTE Confidence: 0.7732424

00:55:28.125 --> 00:55:30.056 for all the patients to tolerate

NOTE Confidence: 0.7732424

00:55:30.056 --> 00:55:31.918 and one of the reasons why you

NOTE Confidence: 0.7732424

00:55:31.918 --> 00:55:34.003 know a lot of people who all the

NOTE Confidence: 0.7732424

00:55:34.003 --> 00:55:36.139 cannot go on pediatric protocols.

NOTE Confidence: 0.7732424

00:55:36.140 --> 00:55:38.436 Can this eliminate usable in a tomb?

NOTE Confidence: 0.7732424

00:55:38.440 --> 00:55:40.736 Up eliminate need for US Virgin eyes?

NOTE Confidence: 0.7732424

00:55:40.740 --> 00:55:42.988 And how do we explain so good outcomes

NOTE Confidence: 0.7732424

00:55:42.988 --> 00:55:45.118 with high perceived cannot be cause

NOTE Confidence: 0.7732424

00:55:45.118 --> 00:55:47.368 younger patients were enrolled well so

NOTE Confidence: 0.7732424

00:55:47.435 --> 00:55:49.955 they tried to enroll patients 14 and older.

NOTE Confidence: 0.7732424

00:55:49.960 --> 00:55:52.529 I think the youngest patients was 17.

NOTE Confidence: 0.7732424

00:55:52.530 --> 00:55:56.247 On that study and the oldest patient was 59,

NOTE Confidence: 0.7732424

00:55:56.250 --> 00:55:58.798 so certainly some of the outcomes can

NOTE Confidence: 0.7732424

00:55:58.798 --> 00:56:01.200 be explained by patient selection,

NOTE Confidence: 0.7732424

00:56:01.200 --> 00:56:03.265 but decent number of these

NOTE Confidence: 0.7732424

00:56:03.265 --> 00:56:05.330 patients have the you know,

NOTE Confidence: 0.7732424

00:56:05.330 --> 00:56:06.188 karyotype abnormalities,

NOTE Confidence: 0.7732424

00:56:06.188 --> 00:56:08.333 Peach like disease and very

NOTE Confidence: 0.7732424

00:56:08.333 --> 00:56:10.700 high number had TP 53 mutations,

NOTE Confidence: 0.7732424

00:56:10.700 --> 00:56:13.325 so it's challenging to say and again

NOTE Confidence: 0.7732424

00:56:13.325 --> 00:56:16.275 you know comparing head to head tag

NOTE Confidence: 0.7732424

00:56:16.275 --> 00:56:18.023 asparaginase containing BFM type

NOTE Confidence: 0.7732424

00:56:18.023 --> 00:56:20.200 protocols with MD Anderson Hyper.

NOTE Confidence: 0.7732424

00:56:20.200 --> 00:56:23.980 See what will not be possible but you know.

NOTE Confidence: 0.7732424

00:56:23.980 --> 00:56:24.944 This is ongoing argument.

NOTE Confidence: 0.7732424

00:56:24.944 --> 00:56:26.830 Which one is better for adult patients?

NOTE Confidence: 0.82373655

00:56:29.170 --> 00:56:31.767 And I think there is one more

NOTE Confidence: 0.82373655

00:56:31.767 --> 00:56:33.612 discussion question to both of

NOTE Confidence: 0.82373655

00:56:33.612 --> 00:56:35.580 you with all this novel Agents

NOTE Confidence: 0.82373655

00:56:35.580 --> 00:56:37.750 of Lena Nine. It is a man.

NOTE Confidence: 0.82373655

00:56:37.750 --> 00:56:40.817 Can you see the use of car T still

NOTE Confidence: 0.82373655

00:56:40.817 --> 00:56:43.087 in the relapse refractory patients?

NOTE Confidence: 0.82373655

00:56:43.090 --> 00:56:44.518 Yeah, you know. So

NOTE Confidence: 0.82373655

00:56:44.520 --> 00:56:45.944 I think there's certainly

NOTE Confidence: 0.82373655

00:56:45.944 --> 00:56:47.724 enroll for car T cells,

NOTE Confidence: 0.82373655

00:56:47.730 --> 00:56:50.278 and we recently had a discussion about

NOTE Confidence: 0.82373655

00:56:50.278 --> 00:56:52.730 young adult who I'm taking care of.

NOTE Confidence: 0.82373655

00:56:52.730 --> 00:56:55.978 And she's actually going for car T cells

NOTE Confidence: 0.82373655

00:56:55.978 --> 00:56:59.547 after she didn't respond to Blender to map.

NOTE Confidence: 0.82373655

00:56:59.550 --> 00:57:02.638 And you know, for some of these patients,

NOTE Confidence: 0.82373655

00:57:02.640 --> 00:57:04.950 it can be a curative treatment.

NOTE Confidence: 0.82373655

00:57:04.950 --> 00:57:06.678 Depending on the construct.

NOTE Confidence: 0.82373655

00:57:06.678 --> 00:57:10.503 So I still hope that some of those patients

NOTE Confidence: 0.82373655

00:57:10.503 --> 00:57:13.740 who fail or who are failed by transplant

NOTE Confidence: 0.82373655

00:57:13.740 --> 00:57:17.508 can be rescued and some well known cases.

NOTE Confidence: 0.82373655

00:57:17.510 --> 00:57:19.080 Nationally where this happened and

NOTE Confidence: 0.82373655

00:57:19.080 --> 00:57:21.240 people survive for many years afterwards.

NOTE Confidence: 0.82373655

00:57:21.240 --> 00:57:23.472 So certainly car T cells is a nice

NOTE Confidence: 0.82373655

00:57:23.472 --> 00:57:25.687 addition to the armamentarium we have

NOTE Confidence: 0.82373655

00:57:25.687 --> 00:57:27.677 for management of these patients.

NOTE Confidence: 0.82373655

00:57:27.680 --> 00:57:28.018 Unfortunately,

NOTE Confidence: 0.82373655

00:57:28.018 --> 00:57:30.046 right now is only for patients

NOTE Confidence: 0.8324077

00:57:30.050 --> 00:57:31.410 or twenty 1625 in.

NOTE Confidence: 0.8313616

00:57:32.890 --> 00:57:34.462 Is only approved for this group

NOTE Confidence: 0.8313616

00:57:34.462 --> 00:57:36.125 of patients and I didn't touch

NOTE Confidence: 0.8313616

00:57:36.125 --> 00:57:37.793 on those studies because I hope

NOTE Confidence: 0.8313616

00:57:37.793 --> 00:57:39.500 some of them will be addressed

NOTE Confidence: 0.8313616

00:57:39.500 --> 00:57:41.444 by the session for two weeks so,

NOTE Confidence: 0.8313616

00:57:41.444 --> 00:57:42.964 but we're hoping that this

NOTE Confidence: 0.8313616

00:57:42.964 --> 00:57:44.476 treatment will become safer and

NOTE Confidence: 0.8313616

00:57:44.476 --> 00:57:46.128 may be used for patients who are

NOTE Confidence: 0.8313616

00:57:46.128 --> 00:57:47.477 all that is definitely something

NOTE Confidence: 0.8313616

00:57:47.477 --> 00:57:49.660 we would like to see for our old

NOTE Confidence: 0.8313616

00:57:49.660 --> 00:57:50.719 LL patients. Yeah,

NOTE Confidence: 0.8313616

00:57:50.719 --> 00:57:53.587 but I'm an maybe at that time we

NOTE Confidence: 0.8313616

00:57:53.587 --> 00:57:56.139 need to just keep in mind that data.

NOTE Confidence: 0.8313616

00:57:56.140 --> 00:57:59.086 Mirali presented with Nina, included in

NOTE Confidence: 0.8313616

00:57:59.086 --> 00:58:03.209 her today is that the prior Lena exposure.

NOTE Confidence: 0.8313616

00:58:03.210 --> 00:58:05.499 May have effect on the Carty outcome,

NOTE Confidence: 0.8313616

00:58:05.500 --> 00:58:07.980 so I think there should be some selection

NOTE Confidence: 0.8313616

00:58:07.980 --> 00:58:11.055 of the patients where we need to right away.

NOTE Confidence: 0.8313616

00:58:11.060 --> 00:58:12.974 Start cleaner if you are really

NOTE Confidence: 0.8313616

00:58:12.974 --> 00:58:14.650 thinking of them offering Cardi,

NOTE Confidence: 0.8313616

00:58:14.650 --> 00:58:17.106 we need to double check whether we need

NOTE Confidence: 0.8313616

00:58:17.106 --> 00:58:19.888 to give those glena front option or not.

NOTE Confidence: 0.8313616

00:58:19.890 --> 00:58:22.306 So I think there should be some selection

NOTE Confidence: 0.8313616

00:58:22.306 --> 00:58:25.120 of the patients who one of the mechanisms

NOTE Confidence: 0.8348592

00:58:25.120 --> 00:58:27.196 of resistance is of course loss

NOTE Confidence: 0.8348592

00:58:27.196 --> 00:58:29.588 of CD 19 expression right so and

NOTE Confidence: 0.8348592

00:58:29.588 --> 00:58:31.772 then you know you lose the target

NOTE Confidence: 0.8348592

00:58:31.844 --> 00:58:33.944 for car T cells so should link.

NOTE Confidence: 0.8348592

00:58:33.950 --> 00:58:36.506 Fortunately it doesn't happen too frequently.

NOTE Confidence: 0.8348592

00:58:36.510 --> 00:58:39.046 So, but nevertheless, the point in world is

NOTE Confidence: 0.8002771

00:58:39.050 --> 00:58:40.946 well taken. Yes no, I agree,

NOTE Confidence: 0.8002771

00:58:40.950 --> 00:58:43.641 and I think one of the things that the

NOTE Confidence: 0.8002771

00:58:43.641 --> 00:58:45.936 investigation that study discussed in this

NOTE Confidence: 0.8002771

00:58:45.936 --> 00:58:47.866 session afterwards with the questions.

NOTE Confidence: 0.8002771

00:58:47.870 --> 00:58:51.195 Is that they would like to understand

NOTE Confidence: 0.8002771

00:58:51.195 --> 00:58:54.168 what was their response to the

NOTE Confidence: 0.8002771

00:58:54.168 --> 00:58:56.588 blender and weather because it

NOTE Confidence: 0.8002771

00:58:56.588 --> 00:58:59.939 may be that even with the karty.

NOTE Confidence: 0.8002771

00:58:59.940 --> 00:59:03.804 I'm sorry even with the CD 19 expression,

NOTE Confidence: 0.8002771

00:59:03.810 --> 00:59:05.970 there's something different about

NOTE Confidence: 0.8002771

00:59:05.970 --> 00:59:08.670 those individuals that needs to

NOTE Confidence: 0.8002771

00:59:08.670 --> 00:59:11.680 be recognized and then the other.

NOTE Confidence: 0.8002771

00:59:11.680 --> 00:59:14.008 Thing is that I think just pairing it

NOTE Confidence: 0.8002771

00:59:14.008 --> 00:59:16.448 with that other study that I presented

NOTE Confidence: 0.8002771

00:59:16.448 --> 00:59:19.050 where the outcomes are better if one

NOTE Confidence: 0.8002771

00:59:19.050 --> 00:59:20.905 receives blina prior to transplant.

NOTE Confidence: 0.8002771

00:59:20.910 --> 00:59:23.689 So one can think about I definitely

NOTE Confidence: 0.8002771

00:59:23.689 --> 00:59:25.250 agree about having car.

NOTE Confidence: 0.8002771

00:59:25.250 --> 00:59:27.644 T in the arm and it arium.

NOTE Confidence: 0.8002771

00:59:27.650 --> 00:59:29.798 But whether one should think about

NOTE Confidence: 0.8002771

00:59:29.798 --> 00:59:32.110 transplant versus party as the next step,

NOTE Confidence: 0.8002771

00:59:32.110 --> 00:59:34.413 and then I think those are those

NOTE Confidence: 0.8002771

00:59:34.413 --> 00:59:36.167 are the complicated equations and

NOTE Confidence: 0.8002771

00:59:36.167 --> 00:59:38.624 we almost have too many choices now.

NOTE Confidence: 0.8002771

00:59:38.630 --> 00:59:39.656 Well, you know,

NOTE Confidence: 0.8002771

00:59:39.656 --> 00:59:41.708 it's nice to have more choices

NOTE Confidence: 0.81426054

00:59:41.710 --> 00:59:43.822 and I wish we have more

NOTE Confidence: 0.81426054

00:59:43.822 --> 00:59:45.490 choices for T cell L.

NOTE Confidence: 0.81426054

00:59:45.490 --> 00:59:47.807 As you know, adults with this disease

NOTE Confidence: 0.81426054

00:59:47.807 --> 00:59:50.290 do not do as well as children.

NOTE Confidence: 0.81426054

00:59:50.290 --> 00:59:51.316 Certainly Laura being.

NOTE Confidence: 0.81426054

00:59:51.316 --> 00:59:52.684 Is that reasonable option,

NOTE Confidence: 0.81426054

00:59:52.690 --> 00:59:56.180 but there are no studies in adults on T cell.

NOTE Confidence: 0.81426054

00:59:56.180 --> 00:59:57.254 Disease of course.

NOTE Confidence: 0.81426054

00:59:57.254 --> 01:00:00.416 Most of the patients have diesel L 85% only.

NOTE Confidence: 0.81426054

01:00:00.416 --> 01:00:02.346 15% have T cell disease,

NOTE Confidence: 0.81426054

01:00:02.350 --> 01:00:03.910 but this is certainly unmet

NOTE Confidence: 0.81426054

01:00:03.910 --> 01:00:06.499 need as not a lot of studies

NOTE Confidence: 0.81426054

01:00:06.499 --> 01:00:08.399 addressing this patients right

NOTE Confidence: 0.7824309

01:00:08.400 --> 01:00:10.776 now, especially adults, and one of

NOTE Confidence: 0.7824309

01:00:10.776 --> 01:00:13.117 the questions which Lloyd is just

NOTE Confidence: 0.7824309

01:00:13.117 --> 01:00:15.175 asking with regard to this discussion

NOTE Confidence: 0.7824309

01:00:15.175 --> 01:00:17.849 of car T versus other newer regions.

NOTE Confidence: 0.7824309

01:00:17.850 --> 01:00:20.489 Can these new region across the CNS?

NOTE Confidence: 0.7824309

01:00:20.490 --> 01:00:23.109 Yeah, you know.

NOTE Confidence: 0.7824309

01:00:23.110 --> 01:00:24.886 It's challenging questions,

NOTE Confidence: 0.7824309

01:00:24.886 --> 01:00:27.846 so you know we know.

NOTE Confidence: 0.7824309

01:00:27.850 --> 01:00:29.494 That you know we're not counting

NOTE Confidence: 0.7824309

01:00:29.494 --> 01:00:31.910 on Blender to my boy Natuzzi map to

NOTE Confidence: 0.7824309

01:00:31.910 --> 01:00:33.794 address CNS disease in these patients

NOTE Confidence: 0.7824309

01:00:33.850 --> 01:00:35.700 were excluded from those studies,

NOTE Confidence: 0.7824309

01:00:35.700 --> 01:00:37.674 so we don't really have those

NOTE Confidence: 0.7824309

01:00:37.674 --> 01:00:39.361 questions answered by the studies

NOTE Confidence: 0.7824309

01:00:39.361 --> 01:00:41.496 which led to the approval of these

NOTE Confidence: 0.7824309

01:00:41.496 --> 01:00:43.547 drugs in regards to car T cells.

NOTE Confidence: 0.7824309

01:00:43.550 --> 01:00:45.314 Again, you know this patients with

NOTE Confidence: 0.7824309

01:00:45.314 --> 01:00:47.000 CNS disease are usually excluded,

NOTE Confidence: 0.7824309

01:00:47.000 --> 01:00:48.332 so we don't know.

NOTE Confidence: 0.7824309

01:00:48.332 --> 01:00:49.997 But we presume that this

NOTE Confidence: 0.7824309

01:00:49.997 --> 01:00:51.090 has to be addressed

NOTE Confidence: 0.8195335

01:00:51.090 --> 01:00:52.398 separately from systemic therapies

NOTE Confidence: 0.8195335

01:00:52.398 --> 01:00:54.360 and there is there are some

NOTE Confidence: 0.8195335

01:00:54.419 --> 01:00:56.105 data from CHOP actually for car,

NOTE Confidence: 0.8195335

01:00:56.110 --> 01:00:57.745 T for CNS positivity and

NOTE Confidence: 0.8195335

01:00:57.745 --> 01:00:59.380 maybe Doctor shopping go into.

NOTE Confidence: 0.8195335

01:00:59.380 --> 01:01:01.210 To that a little more,

NOTE Confidence: 0.8195335

01:01:01.210 --> 01:01:03.040 but there's it's small numbers,

NOTE Confidence: 0.8195335

01:01:03.040 --> 01:01:05.968 but it seems to be covering CNS disease,

NOTE Confidence: 0.8195335

01:01:05.970 --> 01:01:07.430 not necessarily testicular disease.

NOTE Confidence: 0.8195335

01:01:07.430 --> 01:01:08.530 But yes, that

NOTE Confidence: 0.76860124

01:01:08.530 --> 01:01:11.458 is the same as penetration with the Carty,

NOTE Confidence: 0.76860124

01:01:11.460 --> 01:01:13.656 and we have seen the success

NOTE Confidence: 0.76860124

01:01:13.656 --> 01:01:15.058 rate particularly, and again,

NOTE Confidence: 0.76860124

01:01:15.058 --> 01:01:17.396 it's need to be now as parties

NOTE Confidence: 0.76860124

01:01:17.396 --> 01:01:18.410 commercially available.

NOTE Confidence: 0.76860124

01:01:18.410 --> 01:01:21.386 We need to review those data also down

NOTE Confidence: 0.76860124

01:01:21.386 --> 01:01:24.630 the rain so you know, for us, it's a

NOTE Confidence: 0.76860124

01:01:24.630 --> 01:01:26.094 move to, you know,

NOTE Confidence: 0.76860124

01:01:26.094 --> 01:01:28.290 to zoom out Blender to map,

NOTE Confidence: 0.76860124

01:01:28.290 --> 01:01:30.200 you know, without the systemic

NOTE Confidence: 0.76860124

01:01:30.200 --> 01:01:31.728 administration of site error.

NOTE Confidence: 0.76860124

01:01:31.730 --> 01:01:33.368 Why does it say Terminatrix 8?

NOTE Confidence: 0.76860124

01:01:33.370 --> 01:01:35.008 So you know this is certainly

NOTE Confidence: 0.76860124

01:01:35.008 --> 01:01:36.100 a very pertinent issue,

NOTE Confidence: 0.76860124

01:01:36.100 --> 01:01:37.630 which puts a lot of pressure

NOTE Confidence: 0.76860124

01:01:37.630 --> 01:01:38.997 on giving out chemotherapy in

NOTE Confidence: 0.76860124

01:01:38.997 --> 01:01:40.467 adequate numbers to those patients.

NOTE Confidence: 0.76860124

01:01:40.470 --> 01:01:41.830 As we don't know really,

NOTE Confidence: 0.76860124

01:01:41.830 --> 01:01:44.006 you know about the effects of the tool.

NOTE Confidence: 0.7827345

01:01:46.830 --> 01:01:49.990 My last question to Doctor Nikolai and

NOTE Confidence: 0.7827345

01:01:49.990 --> 01:01:52.560 I'm I'm pediatric transplant are so,

NOTE Confidence: 0.7827345

01:01:52.560 --> 01:01:54.765 but looking at this good

NOTE Confidence: 0.7827345

01:01:54.765 --> 01:01:56.529 day to our financials,

NOTE Confidence: 0.7827345

01:01:56.530 --> 01:01:58.294 demandment cleaner to ma'am.

NOTE Confidence: 0.7827345

01:01:58.294 --> 01:02:00.940 Would you consider this in this?

NOTE Confidence: 0.7827345

01:02:00.940 --> 01:02:04.468 You're more than 60 year old older adult,

NOTE Confidence: 0.7827345

01:02:04.470 --> 01:02:06.997 so how you see in changing your

NOTE Confidence: 0.7827345

01:02:06.997 --> 01:02:08.648 practice or your treatment

NOTE Confidence: 0.7827345

01:02:08.648 --> 01:02:11.582 algorithm for those group of LL

NOTE Confidence: 0.7827345

01:02:11.582 --> 01:02:13.730 patient highly scalable patients

NOTE Confidence: 0.7827345

01:02:13.730 --> 01:02:16.466 so you know I think 4.

NOTE Confidence: 0.7827345

01:02:16.470 --> 01:02:19.300 Older patients, the question about

NOTE Confidence: 0.7827345

01:02:19.300 --> 01:02:22.130 transplant is more difficult because

NOTE Confidence: 0.7827345

01:02:22.216 --> 01:02:24.766 you know the outcomes are worse.

NOTE Confidence: 0.7827345

01:02:24.770 --> 01:02:26.961 And the administration of this new drugs

NOTE Confidence: 0.7827345

01:02:26.961 --> 01:02:29.356 give hope that some of these patients

NOTE Confidence: 0.7827345

01:02:29.356 --> 01:02:31.096 may be cured without transplant.

NOTE Confidence: 0.7827345

01:02:31.100 --> 01:02:33.764 Having said that, I don't think we know

NOTE Confidence: 0.7827345

01:02:33.764 --> 01:02:36.419 yet how many of them will be cured,

NOTE Confidence: 0.7827345

01:02:36.420 --> 01:02:38.418 so that's why I cannot clearly

NOTE Confidence: 0.7827345

01:02:38.418 --> 01:02:39.417 answer that question.

NOTE Confidence: 0.7827345

01:02:39.420 --> 01:02:40.398 And I apologize.

NOTE Confidence: 0.7827345

01:02:40.398 --> 01:02:42.354 I have to leave because I'm

NOTE Confidence: 0.7827345

01:02:42.354 --> 01:02:43.748 running that your board,

NOTE Confidence: 0.79139125

01:02:43.750 --> 01:02:45.420 which starts at 1:00 o'clock.

NOTE Confidence: 0.79139125

01:02:45.420 --> 01:02:48.076 When on that note, thank you so much.

NOTE Confidence: 0.79139125

01:02:48.080 --> 01:02:50.446 Tower speakers at Doctor Baddour said doctor

NOTE Confidence: 0.79139125

01:02:50.446 --> 01:02:52.155 catalytic and overloaded and moderate

NOTE Confidence: 0.79139125

01:02:52.155 --> 01:02:54.069 are Doctor Nikita Shad excellent talks.

NOTE Confidence: 0.79139125

01:02:54.070 --> 01:02:56.506 And if you have any additional questions.

NOTE Confidence: 0.79139125

01:02:56.510 --> 01:02:59.065 Feel free to follow up directly with

NOTE Confidence: 0.79139125

01:02:59.065 --> 01:03:02.061 the speakers and we look forward to our

NOTE Confidence: 0.79139125

01:03:02.061 --> 01:03:04.386 next session next Friday about benign

NOTE Confidence: 0.79139125

01:03:04.386 --> 01:03:06.924 hematology and have a great weekend.

NOTE Confidence: 0.79139125

01:03:06.930 --> 01:03:08.088 Everyone take care.

NOTE Confidence: 0.82131004

01:03:09.760 --> 01:03:10.240 Bye bye.